

Ratain Curriculum Vitae – Revised 7/8/2016

MARK J. RATAIN, M.D.

Date of Birth: November 23, 1954
Place of Birth: Washington, D.C.
Marital Status: Married

Education

1976 Harvard University, A.B. (biochemical sciences, magna cum laude)
1980 Yale University School of Medicine, M.D. (thesis -"Elicitation of the late nasal and cutaneous response: the possible role of eosinophils and basophils")

Professional Positions

1972-1977 Computer programmer/systems analyst - part-time. System Sciences, Inc., Bethesda, MD
1980-1981 Intern, Osler Medical Service, Johns Hopkins Hospital, Baltimore, MD
1981-1983 Resident, Osler Medical Service, Johns Hopkins Hospital, Baltimore, MD
1983-1986 Fellow, Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL
1986-1988 Associate Attending Member, Department of Medicine, Division of Hematology/Oncology, Michael Reese Hospital and Medical Center, Chicago, IL
1986-1987 Instructor, Department of Medicine, Section of Hematology/Oncology, and Committee on Clinical Pharmacology, The University of Chicago, Chicago, IL
1987-1991 Assistant Professor, Department of Medicine, Section of Hematology/Oncology, and Committee on Clinical Pharmacology, The University of Chicago, Chicago, IL
1988-1989 Attending Member, Department of Medicine, Division of Hematology/Oncology, Michael Reese Hospital and Medical Center, Chicago, IL
1988-1992 Director of Clinical Pharmacology, Section of Hematology/Oncology, The University of Chicago, Chicago, IL
1991-1995 Director, Developmental Therapeutics Program, Cancer Research Center, The University of Chicago, Chicago, IL
1991-1995 Associate Professor, Department of Medicine, Section of Hematology/Oncology, Committee on Clinical Pharmacology, and Cancer Research Center, The University of Chicago, Chicago, IL
1992-2010 Chairman, Committee on Clinical Pharmacology and Pharmacogenomics*, The University of Chicago, Chicago, IL
1995-2002 Professor, Department of Medicine, Section of Hematology/Oncology, Committee on Clinical Pharmacology and Pharmacogenomics*, and Cancer Research Center, The University of Chicago, Chicago, IL

Ratain Curriculum Vitae – Revised 7/8/2016

1995-2000 Co-Director, Clinical and Experimental Therapeutics Program, Cancer Research Center, The University of Chicago, Chicago, IL

2002- Leon O. Jacobson Professor, Department of Medicine, Section of Hematology/Oncology, Committee on Clinical Pharmacology and Pharmacogenomics , and Comprehensive Cancer Center^t, The University of Chicago, Chicago, IL

1999- Associate Director for Clinical Sciences, Comprehensive Cancer Center^t, The University of Chicago, Chicago, IL

2010- Director, Center for Personalized Therapeutics, The University of Chicago, Chicago, IL

2010- Chief Hospital Pharmacologist, The University of Chicago Medicine[&], Chicago, IL

^{*}previously Committee on Clinical Pharmacology

^tpreviously Cancer Research Center

[&]previously University of Chicago Medical Center

Ratain Curriculum Vitae – Revised 7/8/2016

Research Review and Related Federal Service

National Institutes of Health

Ad Hoc Reviewer, Experimental Therapeutics Study Section, Division of Research Grants 1986
Special Review Committee, National Cancer Institute 1991
Consultant Reviewer, Department of Veteran Affairs 1993
Ad Hoc Reviewer, National Cancer Institute 1993
Special Study Section (Small Business Innovative Research Program), Division of Research Grants 1994
Ad Hoc Reviewer, National Center for Research Resources 1997
Reviewer, Intramural Review Office, Pediatric Oncology Branch, National Cancer Institute 1998
Clinical Oncology Special Emphasis Panel, Oncological Science Initial Review Group, Center for Scientific Review 1999-2000
Clinical Advisory Working Group, National Institute of General Medical Sciences 1999
Ad Hoc Reviewer, Drug Development Group, National Cancer Institute 2000, 2001
Data and Safety Monitoring Board (T-Cell Depleted Auto Stem Cell Transplant Trial for Systemic Sclerosis), National Institute of Arthritis and Musculoskeletal Diseases 2002-2005
Clinical Trials Working Group, National Cancer Advisory Board, National Cancer Institute 2004-2005
Investigational Drug Steering Committee, National Cancer Institute 2005-2016 (Co-Chair, Steering Committee, 2005-2008; Co-Chair, Clinical Trials Design Task Force, 2012-2016)
National Institute of General Medical Sciences Special Emphasis Panel 2006
Subcommittee J - Population and Patient-Oriented Training, National Cancer Institute Initial Review Group (Ad Hoc Reviewer 2006; Member 2006-2009)
Reviewer, NIH Director's New Innovator Awards 2008
Reviewer, Center for Scientific Review 2010
National Institute of General Medical Sciences Special Emphasis Panel 2013, 2014

Dutch Cancer Society

Ad Hoc Reviewer 1994, 1999

The Cancer Society of New Zealand

Ad Hoc Reviewer 1994

Joint Infrastructure Fund, Wellcome Trust

Ad Hoc Reviewer 1998, 2000

Institut National du Cancer

Ad Hoc Reviewer 2010

Christian Doppler Research Association

Ad Hoc Reviewer 2011

Pennsylvania Department of Health

Ad Hoc Reviewer 2012-2014, 2016

Florida Department of Health

Ad Hoc Reviewer 2015-2016

Ratain Curriculum Vitae – Revised 7/8/2016

National and International Organizations

Cancer and Leukemia Group B

Chemotherapy Committee 1988-1990
Breast Committee 1989-1998
Ad Hoc Committee on Relations with Pharmaceutical Companies 1989-1990
Pharmacology and Experimental Therapeutics Committee 1990-2011 (Chair, 1994-2011)
Ad Hoc Nominating Committee 1989-1990
Industrial Relations Committee 1992-1993
Executive Committee 1993-1996
Board of Directors 1993-2011
Chair, Ad Hoc Committee on Conflict of Interest 1994-1996
Chair, Conflict of Interest Committee 1996-1998

American Federation for Clinical Research

Medical School Representative 1988-1989

American Society for Clinical Pharmacology and Therapeutics

Hematologic and Neoplastic Diseases Section 1988-2007 (Vice Chair, 1988-1992; Chair, 1992-1995)
Government Affairs Committee 1990-2002 (Vice Chair, 1997-2002)
Long Range Planning Committee 1990-1993
Committee on Coordination of Scientific Sections 1992-1995, 1998-2001 (Chair, 1998-2001)
Scientific Program Committee 1993-1994, 1996-1998, 2001-2004 (Vice Chair 2001-2002, Chair 2002-2003, Immediate Past Chair 2003-2004)
Nominating Committee 1995-1996
Board of Directors 1997-2001
Executive Committee 1998-2001
Communications and Public Relations Committee 1998-2001
Committee on Substance Abuse 1998-2001
Membership Committee 2000-2003
Molecular Pharmacology and Pharmacogenetics Section 2001-
Pharmacokinetics and Drug Metabolism Section 2001-2007
Oncology Section 2007-
Pharmacometrics and Pharmacokinetics 2007-

International Workshops on Pharmacodynamics of Anticancer Agents

First International Workshop on Pharmacodynamics of Anticancer Agents (Fontana, WI), Co-Organizer 1989
Second International Workshop on Pharmacodynamics of Anticancer Agents (Eze, France), Co-Organizer 1992
Third International Workshop on Pharmacodynamics of Anticancer Agents (Irvington, VA), Co-Organizer 1995
Fourth International Workshop on Pharmacodynamics of Anticancer Agents (Dunkeld, Scotland), Co-Organizer 1998
Fifth International Workshop on Pharmacodynamics of Anticancer Agents (Sea Island, GA), Co-Organizer 2001
Sixth International Workshop on Pharmacodynamics of Anticancer Agents (Venice, Italy), Co-Organizer 2004
Seventh International Workshop on Pharmacodynamics of Anticancer Agents (Guanacaste, Costa Rica), Co-Organizer 2007
Eighth International Workshop on Pharmacodynamics of Anticancer Agents (Hakone, Japan), Co-Organizer 2010
Ninth International Workshop on Pharmacodynamics of Anticancer Agents (Hexham, England), Co-Organizer 2013
Tenth International Workshop on Pharmacodynamics of Anticancer Agents (Skamania, WA), Co-Organizer 2016

Ratain Curriculum Vitae – Revised 7/8/2016

American Society of Clinical Oncology

Committee for Patient Advocacy 1990-1992
Audit and Finance Committee 1990-1994 (Chair, 1990-1994)
Secretary-Treasurer 1994-1997
Board of Directors 1994-1997
Executive Committee 1994-1997
Strategic Planning Committee 1994-1998
Program Committee 1995-1997, 1998-2000 (Subchair for Clinical Pharmacology, 1995-1996;
Board Liaison, 1995-1996)
Industry/Exhibits Committee 1995-1997 (Board Liaison, 1995-1997)
Ad Hoc Committee to Develop ASCO OnLine 1995
Clinical Methods Workshop Program Committee 1995-1997
OnLine Committee 1995-2000
Subcommittee on Phase I Clinical Trials, Public Issues Committee 1996 (Chair, 1996)
Publications Committee 1997-2000 (OnLine Committee Liaison 1997-2000)
Continuing Medical Education Committee 1997-2000 (Chair, 1997-1999; Immediate Past Chair,
1999-2000)
Cancer Education Committee 2000-2003 (Track Team Leader, Pharmacology/Drug Development,
2002-2003)
Translational Research Task Force 2005
Cancer Research Committee 2007-2010 (Chair, Pre-Phase III Working Group 2008-2010)

European Organization for Research and Treatment of Cancer

Pharmacology and Molecular Mechanisms Group (Corresponding Member) 1990-2004

National Board of Medical Examiners

Step 3 Test Material Development Committee for Utilization of Resources, United States Medical
Licensing Examination 1997-1998

Pharmacogenomics (previously Pharmacogenetics) of Anticancer Agents Research Group

Founding Chair 2000-2015

Pharmacogenomics (previously Pharmacogenetics) Research Network

Steering Committee 2000-2015 (Chair, 2000-2003)
Coordinating Committee 2003-2004, 2007-2008
Cancer Partnerships Working Group 2006-2010 (Co-Chair, 2006-2010)

U.S. Pharmacopeia

Oncologic Disease Expert Committee 2000-2003

Institut Pasteur Euroconferences

Pharmacogenomics 2, Scientific Committee 2001-2002

American Board of Clinical Pharmacology

Governing Board 2002-2007
Credentials Committee 2002-2007 (Chair, 2004-2007)

American Association for Cancer Research

Program Committee 2002-2003, 2006-2007, 2012-2013, 2014-
Scientific Committee AACR-EORTC-NCI Symposia 2003-2006
Education Committee 2006-2007
Pancreatic Cancer Action Network-AACR Research Acceleration Network Grant Scientific Review
Committee 2012-2015

Accreditation Council for Continuing Medical Education

Content Validation Advisory Group 2003

Ratain Curriculum Vitae – Revised 7/8/2016

Sapporo Cancer Seminar Foundation
25th International Symposium, Organizing Committee 2005

Japanese Foundation for Cancer Research
International Symposia, Member 2007-2014

The ASCO Foundation
Translational Research Professorship Review Subcommittee 2007-2008

Alliance for Clinical Trials in Oncology
Pharmacogenomics and Population Pharmacology Committee 2011- (Chair, 2011-)

International Workshops on Dose Optimization Strategies for Targeted Drugs
1st International Workshop on Dose Optimization Strategies for Targeted Drugs: Focus on
Oncolytics (Zaandam, Netherlands), Co-Chair 2015

Ratinal Curriculum Vitae – Revised 7/8/2016

Institutional Committees

Michael Reese Hospital and Medical Center

Intern Selection Committee, Department of Medicine 1987-1988
Institutional Review Board, Alternate 1988-1989
Pharmacy, Therapeutics and Antibiotic Committee 1988-1989

The University of Chicago

Chairman, Office of Research Services Faculty Advisory Committee, Biological Sciences Division
1992-1995

Executive Committee, Cancer Research Center 1992-2004

Divisional Executive Committee, Biological Sciences Division 1992-2009

Clinical Chairmen's Committee, Biological Sciences Division 1992-2007

American Cancer Society Institutional Research Grant Committee, Cancer Research Center
1994-1998

Clinical Trials Director Search Committee, Department of Health Studies 1997-1998

Co-Chair, Pharmacoepidemiology Search Committee 1998-1999

Chair, Entrepreneurs Committee, Department of Medicine 1999-2000

Radiology Search Committee, Biological Sciences Division 2000-2001

Committee on Appointments and Promotions, Biological Sciences Division 2000-2004

Chair, Clinical Research Working Group, Department of Medicine 2000-2001

Protocol Accrual Closure and Monitoring Committee, Cancer Research Center 2000-2001

Committee on Intellectual Property 2001-2004

Population Sciences Search Committee, Cancer Research Center 2001

Human Genetics Search Committee, Biological Sciences Division 2002-2003

Cancer Advisory Committee, Comprehensive Cancer Center[†] 2004-

Clinical Research Oversight Committee, Cancer Research Center 2004- (Chair 2004-2007)

Cardiology Search Committee, Department of Medicine 2005-2006

Entrepreneurial and Translational Science Advisory Committee, Department of Medicine 2006-
2007

Clinical Research Advisory Committee, Comprehensive Cancer Center[†] 2007- (Chair 2007-)

Executive Committee, Comprehensive Cancer Center[†] 2008-

UChicago Tech Faculty Advisory Committee, 2008-2010

Chicago Innovation Initiative Working Group, 2012-2013

Research Strategy Steering Committee, Department of Medicine 2016-

The University of Chicago Medicine

Risk Management and Patient Safety Executive Committee, 2013-

Ratain Curriculum Vitae – Revised 7/8/2016

Service to Other Institutions

Georgetown University

External Scientific Advisory Committee, Lombardi Cancer Center 2002-2011

St. Jude Children’s Research Hospital

External Advisory Board, Cancer Center 2005-

The First People’s Hospital Affiliated Shanghai Jiangtong University

External Scientific Advisor in Pharmacogenetics, The Shanghai Transplantation Research Center
2008

Thomas Jefferson University

External Scientific Advisory Committee, Kimmel Cancer Center 2009-2013

Radboud University

Scientific Advisory Board, EuroTARGET 2011-

Dartmouth University

External Scientific Advisory Board, Norris Cotton Cancer Center 2013-

University of Texas Southwestern

External Advisory Board, Kidney SPORE 2014-

U-PGx Consortium

Scientific Advisory Board 2016-

National University Cancer Centre Singapore

Scientific Advisory Board 2016-

Regional Committees

1987-1992	New Agents Committee, Illinois Cancer Council
1987-1992	Biological Response Modifiers Committee, Illinois Cancer Council
1989-1992	Chemoprevention Committee, Illinois Cancer Council
1990-1991	Illinois Division Research Committee, American Cancer Society

Certification

1981	Diplomate, National Board of Medical Examiners
1983	Licensed Physician and Surgeon, State of Illinois
1983	Diplomate, American Board of Internal Medicine
1985	Diplomate, Medical Oncology, American Board of Internal Medicine
1986	Diplomate, Hematology, American Board of Internal Medicine
1993	Diplomate, American Board of Clinical Pharmacology
2014-	Maintenance of Certification, Internal Medicine, Medical Oncology, and Hematology, American Board of Internal Medicine

Ratain Curriculum Vitae – Revised 7/8/2016

Professional Membership

- 1983- American College of Physicians (Fellow, 1990)**
- 1986- American Association for the Advancement of Science**
- 1986- American Society of Clinical Oncology (Fellow, 2007)**
- 1986- American Federation for Clinical Research**
- 1987- American Society for Clinical Pharmacology and Therapeutics**
- 1988- American Association for Cancer Research**
- 1988- American Society of Hematology**
- 1990- Central Society for Clinical Research**
- 1992- European Society for Medical Oncology**
- 2007- Association of American Physicians**
- 2011- American College of Clinical Pharmacology (Honorary Fellow, 2011)**

Ratna Curriculum Vitae – Revised 7/8/2016

Honors and Awards

1975	Dreyfus Fellowship, Harvard University, Department of Biochemistry
1985	Central Society for Clinical Research, Trainee Award
1993	Unit Award, Pharmaceutical Research and Manufacturers of America Foundation
1994-	Listed in <u>The Best Doctors in America</u> (Woodward/White)
1997-	Listed in <u>Chicago's Top Doctors</u> , <u>Chicago</u>
1999	Honorary Visiting Expert, Ministry of Health, Singapore
1999-	Listed in <u>America's Top Doctors</u> (Castle Connolly)
2001	Distinguished Lecturer, Cancer Institute of New Jersey
2002-	Listed in <u>Top Doctors: Chicago Metro Area</u> (Castle Connolly)
2002-	Leon O. Jacobson Professorship, The University of Chicago
2004	Top Membership Recruiter, American Society for Clinical Pharmacology and Therapeutics
2005-	Listed in <u>America's Top Doctors for Cancer</u> (Castle Connolly)
2005	Special Recognition Award, National Cancer Institute
2006	Chair, 60 th Annual Senior Scientific Session, The University of Chicago
2007	Elected to Association of American Physicians
2007	Statesman Award, American Society of Clinical Oncology
2008	Emil J. Freireich Award for Clinical Research, MD Anderson Cancer Center
2008	Institute for Pharmacogenomics and Individualized Therapy Clinical Service Award, The University of North Carolina at Chapel Hill
2009	Director's Service Award, National Cancer Institute
2009	Research Achievement Award in Clinical Pharmacology and Translational Research, American Association of Pharmaceutical Scientists
2010	Rawls-Palmer Progress in Medicine Award, American Society for Clinical Pharmacology and Therapeutics
2010	Henry T. Lynch Lectureship in Medical Genetics, NorthShore University Health System
2011	Robert Hart Waldman, M.D., Lecture, The University of Nebraska Medical Center
2011	Translational Research Professorship, American Society of Clinical Oncology
2011	Certificate of Appreciation, Japanese Society of Medical Oncology
2011	Honorary Fellow, American College of Clinical Pharmacology
2012	Visiting Professor, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Clinical Pharmacology
2012	Special Recognition, Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah
2013	Spotlight on Science Featured Speaker, American Society of Health System Pharmacists
2014	Keynote Speaker, University of Illinois College of Medicine Research Symposium
2014	Keynote Speaker, Hospital Pharmacy Europe Live
2014	Keynote Speaker, Emory University Phase I Unit Five Year Celebration
2015	Award in Excellence in Clinical Pharmacology, Pharmaceutical Research and Manufacturers of America Foundation
2016	Nominee (Scientific Advances), Giants of Cancer Care, OncLive
2016	Gustave-Roussy Award, Sociedad Franco Brasileira de Oncologia

Ratain Curriculum Vitae – Revised 7/8/2016

Significant Editorial Responsibilities

1990-2003	<u>Cancer Chemotherapy and Pharmacology</u> , Editorial Board
1994-1996	<u>Clinical Cancer Research</u> , Editorial Board
1995-	<u>Investigational New Drugs</u>, Editorial Advisory Board
1996-2002	<u>Clinical Cancer Research</u> , Associate Editor
1999-2001	<u>Clinical Pharmacology and Therapeutics</u> , Editorial Advisory Committee
1999	<u>Classic Papers and Current Comments: Clinical Pharmacology</u> , Guest Editor
2001-2007	<u>Journal of Clinical Oncology</u> , Associate Editor
2001-2004	<u>Current Pharmacogenomics</u> , Editor-in-Chief
2001-2008	<u>Clinical Pharmacology and Therapeutics</u> , Editorial Board
2003-	<u>Clinical Advances in Hematology & Oncology</u>, Section Editor in Oncology
2003-2009	<u>Clinical Cancer Research</u> , Editorial Board
2005-	<u>Pharmacogenetics and Genomics</u>, Co-Editor-in-Chief
2012-	<u>Clinical Cancer Research</u>, Editorial Board

Patents

1998	Camptothecin drug combinations and methods with reduced side effects (inventors Mark J. Ratain & Elora Gupta), United States Patent No.: 5,786,344 (7/28/1998)
2002	Methods for detection of promoter polymorphism in a UGT gene promoter (inventors Anna Di Rienzo, Lalitha Iyer & Mark J. Ratain), United States Patent No.: 6,395,481 (5/28/2002)
2002	Methods for detection of promoter polymorphism in a UGT gene promoter (inventors Anna Di Rienzo, Lalitha Iyer & Mark J. Ratain), United States Patent No.: 6,472,157 (10/29/2002)
2004	Camptothecin drug combination and methods with reduced side effects (inventors Mark J. Ratain & Elora Gupta), European Patent No.: 0768895 (9/22/2004)
2008	Methods and compositions for predicting irinotecan toxicity (inventors Mark J. Ratain, Federico Innocenti, Anna Di Rienzo & Carrie Grimsley), European Patent No.: 1629111 (5/28/2008)
2010	Methods for predicting irinotecan toxicity (inventors Mark J. Ratain, Federico Innocenti, Anna Di Rienzo & Carrie Grimsley), United States Patent No.: 7,807,350 (10/5/2010)
2014	Method for identification of sensitivity of a patient to telomerase inhibition therapy (inventors Calvin B. Harley, Laurence Elias, Jennifer Smith, Mark J. Ratain, Fabio Benedetti), United States Patent No.: 8,877,723 (11/4/2014)

Mailing Address:

Mark J. Ratain, M.D.
The University of Chicago Medicine
MC2115
5841 S. Maryland Avenue
Chicago, Illinois 60637
Email: mratain@medicine.bsd.uchicago.edu or mjr1@uchicago.edu
Telephone: (773) 702-4400
Fax: (773) 702-3969

Ratain Curriculum Vitae – Revised 7/8/2016

Original Research Articles

1. Ratain MJ, Golomb HM, Vardiman JW, Vokes EE, Jacobs RH, Daly K. Treatment of hairy cell leukemia with recombinant alpha-2-interferon. *Blood* 65, 644-648 (1985).
2. Bardawil RG, Groves C, Ratain MJ, Golomb HM, Vardiman JW. Changes in peripheral blood and bone marrow specimens following therapy with recombinant alpha₂ interferon for hairy cell leukemia. *Am J Clin Path* 85, 194-201 (1986).
3. Golomb HM, Jacobs A, Fefer A, Ozer H, Thompson J, Portlock C, Ratain M, Golde D, Vardiman J, Burke J, Brady J, Bonnem E, Spiegel R. Alpha-2 interferon therapy of hairy cell leukemia: A multicenter study of 64 patients. *J Clin Oncol* 4, 900-905 (1986).
4. Schilsky RL, O'Laughlin K, Ratain MJ. Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum (II) in patients with advanced cancer. *Cancer Res* 46, 4184-4188 (1986).
5. Ratain MJ, Vogelzang NJ. Phase I and pharmacological study of vinblastine by prolonged continuous infusion. *Cancer Res* 46, 4827-4830 (1986).
6. Bennett CL, Vogelzang NJ, Ratain MJ, Reich S. Hyponatremia and other toxic effects during a phase I trial of recombinant human gamma interferon and vinblastine. *Cancer Treat Rep* 70, 1081-1084 (1986).
7. Ratain MJ, Vogelzang NJ, Sinkule JA. Interpatient and inpatient variability in vinblastine pharmacokinetics. *Clin Pharmacol Ther* 41, 61-67 (1987).
8. Ratain MJ, Golomb HM, Bardawil RG, Vardiman JW, Westbrook CA, Kaminer LS, Lembersky BC, Bitter MA, Daly K. Durability of responses to interferon alfa-2b in advanced hairy cell leukemia. *Blood* 69, 872-877 (1987).
9. Vokes EE, Bitter MA, Ratain MJ, Prystowsky MB, Daly K, Golomb HM. Flow cytometry in hairy cell leukemia before and during interferon alfa-2b therapy. *Cancer* 59, 1987-1991 (1987).
10. Ratain MJ, Vogelzang NJ. Limited sampling model for vinblastine pharmacokinetics. *Cancer Treat Rep* 71, 935-939 (1987).
11. Ratain MJ, Kaminer LS, Bitran JD, Larson RA, LeBeau MM, Skosey C, Purl S, Hoffman PC, Wade J, Vardiman JW, Daly K, Rowley JD, Golomb HM. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small cell carcinoma of the lung. *Blood* 70, 1412-1417 (1987).
12. Vogelzang NJ, Ruane M, Ratain MJ, Dhowlatshahi K, Chodak GW. A programmable and implantable pumping system for systemic chemotherapy: A performance analysis in 52 patients. *J Clin Oncol* 5, 1968-1976 (1987).
13. Lembersky BC, Ratain MJ, Westbrook C, Golomb HM. Rapid response to 2'deoxycoformycin in advanced hairy cell leukemia after failure of interferons alpha and gamma. *Amer J Hematol* 27, 60-62 (1988).
14. Golomb HM, Ratain MJ, Fefer A, Thompson J, Golde DW, Ozer H, Portlock C, Silber R, Rapoport J, Bonnem E, Spiegel R, Tensen L, Burke JS, Vardiman JW. Randomized study of the duration of treatment with interferon alfa-2b in patients with hairy cell leukemia. *J Natl Cancer Inst* 80, 369-373 (1988).
15. Vardiman JW, Gilewski TA, Ratain MJ, Bitter MA, Bradlow BA, Golomb HM. Evaluation of Leu M-5 (CD11c) in hairy cell leukemia by the alkaline phosphatase anti-alkaline phosphatase technique. *Am J Clin Path* 90, 250-256 (1988).
16. Lembersky BC, Ratain MJ, Golomb HM. Skeletal complications in hairy cell leukemia: diagnosis and therapy. *J Clin Oncol* 6, 1280-1284 (1988).
17. Ratain MJ, Staubus AE, Schilsky RL, Malspeis L. Limited sampling models for amonafide (NSC 308847) pharmacokinetics. *Cancer Res* 48, 4127-4130 (1988).

Ratain Curriculum Vitae – Revised 7/8/2016

18. Ackland SP, Choi KE, Ratain MJ, Egorin MJ, Williams SF, Sinkule JA, Bitran JD. Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide. *J Clin Oncol* 6, 1192-1196 (1988).
19. Ratain MJ, Vardiman JW, Barker CM, Golomb HM. Prognostic variables in hairy cell leukemia after splenectomy as initial therapy. *Cancer* 62, 2420-2424 (1988).
20. Ratain MJ, Golomb HM, Vardiman JW, Westbrook CA, Barker C, Hooberman A, Bitter MA, Daly K. Relapse after interferon alfa-2b therapy for hairy-cell leukemia: Analysis of prognostic variables. *J Clin Oncol* 6, 1714-1721 (1988).
21. Ratain MJ, Schilsky RL, Wojack BR, Simon T, Senekjian E, Vogelzang NJ. Hydroxyurea and etoposide: *In vitro* synergy and phase I clinical trial. *J Natl Cancer Inst* 80, 1412-1416 (1988).
22. Ackland SP, Ratain MJ, Vogelzang NJ, Choi KE, Ruane M, Sinkule JA. Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin. *Clin Pharmacol Ther* 45, 340-347 (1989).
23. Vokes EE, Schilsky RL, Choi KE, Magid DM, Guarnieri CM, Whaling SM, Ratain MJ, Weichselbaum RR, Panje WR. A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. *Cancer* 63, 30-36 (1989).
24. Ratain MJ, Schilsky RL, Choi KE, Guarnieri C, Grimmer D, Vogelzang NJ, Senekjian E, Liebner MA. Adaptive control of etoposide dosing: Impact of interpatient pharmacodynamic variability. *Clin Pharmacol Ther* 45, 226-233 (1989).
25. Choi KE, Ratain MJ, Williams SF, Golick JA, Beschoner JC, Fullem L, Bitran JD. Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion. *Cancer Res* 49, 1318-1321 (1989).
26. Egorin MJ, Forrest A, Belani CP, Ratain MJ, Abrams JS, Van Echo DA. A limited sampling strategy for cyclophosphamide pharmacokinetics. *Cancer Res* 49, 3129-3133 (1989).
27. Moormeier J, Ratain MJ, Vardiman JW, Daly K, Golomb HM. Low dose interferon in hairy cell leukemia. *J Natl Cancer Inst* 81, 1172-1174 (1989).
28. Moormeier J, Westbrook CA, Ratain MJ, Golomb HM. Interferon alfa-2B antibodies and clinical resistance in a patient with hairy cell leukemia. *Leukemia Lymphoma* 1, 43-45 (1989).
29. Johnston C, Senekjian EK, Ratain MJ, Talerman A. Conservative management of primary cervical lymphoma using combination chemotherapy: a case report. *Gynecol Oncol* 35, 391-394 (1989).
30. Schilsky RL, Ratain MJ. Clinical pharmacokinetics of high dose leucovorin after intravenous and oral administration. *J Natl Cancer Inst* 82, 1411-1415 (1990).
31. Richards JM, Mick R, Latta JM, Daly K, Ratain MJ, Vardiman JW, Golomb HM. Serum soluble IL-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. *Blood* 76, 1941-1945 (1990).
32. Ratain MJ, Robert J, van der Vijgh WJF. Limited sampling models for doxorubicin pharmacokinetics. *J Clin Oncol* 9, 871-876 (1991).
33. Vokes EE, Ratain MJ, Janisch L, Hoffman PC, Golomb HM, Schilsky RL. A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients. *Eur J Cancer* 27, 217-218 (1991).
34. Golomb HM, Fefer A, Golde DW, Ozer H, Portlock C, Silber R, Rapoport J, Ratain MJ, Thompson J, Bonnem E, Spiegel R, Tensen L, Burke JS, Vardiman JW. Survival experience of 195 patients with hairy cell leukemia treated in a multi-institutional study with interferon-alfa 2b. *Leukemia Lymphoma* 4, 99-102 (1991).

Ratain Curriculum Vitae – Revised 7/8/2016

35. Vokes EE, Raschko JW, Vogelzang NJ, Warfield EE, Ratain MJ, Doroshow JH, Schilsky RL. Five day infusion fluorodeoxyuridine with high dose oral leucovorin: A phase I study. *Cancer Chemother Pharmacol* 28, 69-73 (1991).
36. Ratain MJ, Mick R, Schilsky RL, Vogelzang NJ, Berezin F. Pharmacologically-based dosing of etoposide: A means of safely increasing dose-intensity. *J Clin Oncol* 9, 1480-1486 (1991).
37. Golomb HM, Ratain MJ, Fefer A, Thompson J, Portlock CS, Ozer H, Mick R, Chiavello J, Israel RJ, Bonnem EM. Low dose interferon alfa-2B for the induction of remission of hairy cell leukemia: A multi-institutional study of 49 patients. *Leukemia Lymphoma* 5, 335-340 (1991).
38. Platanius LC, Miller CB, Mick R, Hart RD, Ozer H, McEvilly JM, Jones RJ, Ratain MJ. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. *J Clin Oncol* 9, 2021-2026 (1991).
39. Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Williams SF, Smiddy J. Paradoxical relationship between acetylator phenotype and amonafide toxicity. *Clin Pharmacol Ther* 50, 573-579 (1991).
40. Mick R, Ratain MJ. Modeling interpatient pharmacodynamic variability of etoposide. *J Natl Cancer Inst* 83, 1560-1564 (1991).
41. Vokes EE, Moormeier JA, Ratain MJ, Egorin MJ, Haraf DJ, Mick R, Weichselbaum RR. 5-fluorouracil, hydroxyurea, and escalating doses of continuous infusion cisplatin with concomitant radiotherapy: A clinical and pharmacologic study. *Cancer Chemother Pharmacol* 29, 178-184 (1992).
42. Miller CB, Platanius LC, Mills SR, Zahurak ML, Ratain MJ, Ettinger DS, Jones RJ. A phase I/II trial of erythropoietin in the treatment of cisplatin-associated anemia. *J Natl Cancer Inst* 84, 98-103 (1992).
43. Kodish E, Stocking C, Ratain MJ, Kohrman A, Siegler M. Ethical issues in phase I oncology research: A comparison of investigators and IRB chairpersons. *J Clin Oncol* 10, 1810-1816 (1992).
44. Golomb HM, Ratain MJ, Mick R, Daly K. Interferon treatment for hairy cell leukemia; an update on a cohort of 69 patients treated from 1983-86. *Leukemia* 6,1177-1180 (1992).
45. Schilsky RL, Ratain MJ, Janisch L, Vogelzang NJ, Lucas VS, Ravitch J, Hohneker JA, Clendenin NJ, Tuttle RL. Phase I clinical and pharmacologic study of 502U83 administered as a 24 hour continuous intravenous infusion. *Cancer Chemother Pharmacol* 31, 283-288 (1993).
46. Vokes EE, Ratain MJ, Mick R, McEvilly JM, Haraf D, Hamasaki V, Kozloff M, Weichselbaum RR, Panje WR, Wenig B, Berezin F. Cisplatin, 5-fluorouracil and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. *J Clin Oncol* 11, 360-368 (1993).
47. Mick R, Ratain MJ. Model-guided determination of maximal tolerated dose in phase I clinical trials: Evidence for increased precision. *J Natl Cancer Inst* 85, 217-223 (1993).
48. Ratain MJ, Priest E, Janisch L, Vogelzang NJ. Phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a. *Cancer* 71, 2371-2376 (1993).
49. Schilsky RL, Janisch L, Berezin F, Mick R, Vogelzang NJ, Ratain MJ. Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer. *Cancer Res* 53, 1293-1296 (1993).
50. Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Vogelzang NJ, Lane LB. Phase I study of amonafide dosing based on acetylator phenotype. *Cancer Res* 53, 2304-2308 (1993).

Ratain Curriculum Vitae – Revised 7/8/2016

51. Vokes EE, Dolan ME, Krishnasamy S, Mick R, Ratain MJ, Berezin F, Brachman D, Whitman G, Schilsky RL, Weichselbaum RR, Charette J, Dohrmann GJ, Hekmatpanah J. 5-fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis. *Ann Oncol* 4, 591-595 (1993).
52. Vokes EE, O'Brien S, Vogelzang NJ, Schilsky RL, Ratain MJ. Five day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alfa-2b: a phase I study. *Cancer Chemother Pharmacol* 32, 347-352 (1993).
53. Lichtman SM, Ratain MJ, Van Echo DA, Rosner G, Egorin MJ, Budman DR, Norton L, Vogelzang NJ, Schilsky RL. Phase I trial of granulocyte-macrophage colony stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. *J Natl Cancer Inst* 85, 1319-1326 (1993).
54. Samuels BL, Mick R, Vogelzang NJ, Williams SF, Schilsky RL, Safa AR, O'Brien S, Ratain MJ. Modulation of vinblastine resistance with cyclosporine A: a phase I study. *Clin Pharmacol Ther* 54, 421-429 (1993).
55. Vogelzang NJ, Mick R, Janisch L, Berezin F, Schilsky RL, Ratain MJ. A phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). *Cancer Res* 54, 114-119 (1994).
56. Devine SM, Ratain MJ, Janisch L, Richards JM, Williams SF, Schilsky RL, Vogelzang NJ, Skosey C. Phase I trial of thiotepa, granulocyte-macrophage colony stimulating factor and prednisone or pentoxifylline in patients with refractory solid tumors. *Oncol Rep* 1, 213-216 (1994).
57. Platanius LC, Ratain MJ, O'Brien S, Larson RA, Vardiman JW, Shaw JP, Williams SF, Baron JM, Parker K, Woodworth TG. Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB₄₈₆ IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. *Leukemia Lymphoma* 14, 257-262 (1994).
58. Fleming GF, Ratain MJ, O'Brien SM, Schilsky RL, Hoffman PC, Richards JM, Vogelzang NJ, Kasunic DA, Earhart RH. Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. *J Natl Cancer Inst* 86, 368-372 (1994).
59. Mick R, Ratain MJ. Bootstrap validation of pharmacodynamic models defined by way of stepwise linear regression. *Clin Pharmacol Ther* 56, 217-222 (1994).
60. Kobayashi K, Vogelzang NJ, O'Brien SM, Schilsky RL, Vokes EE, Ratain MJ. A phase I study of intermittent infusion cladribine in patients with solid tumors. *Cancer* 74, 168-173 (1994).
61. Mitchell RB, Dolan ME, Janisch L, Vogelzang NJ, Ratain MJ, Schilsky RL. Sequential therapy with dacarbazine and carmustine: A phase I study. *Cancer Chemother Pharmacol* 34, 509-514 (1994).
62. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan (CPT-11) in humans: correlation of glucuronidation with diarrhea. *Cancer Res* 54, 3723-3725 (1994).
63. Janisch L, Mick R, Schilsky RL, Vogelzang NJ, O'Brien S, Kut M, Ratain MJ. Prognostic factors for survival in patients treated on phase I clinical trials. *Cancer* 74, 1965-1973 (1994).
64. Mick R, Lane N, Daugherty C, Ratain MJ. Physician-determined patient risk of toxicity: impact on enrollment and decision making in phase I cancer trials. *J Natl Cancer Inst* 86, 1685-1693 (1994).
65. Karlsson MO, Port RE, Ratain MJ, Sheiner LB. A population model for the leukopenic effect of etoposide. *Clin Pharmacol Ther* 57, 325-334 (1995).
66. Ratain MJ, Rosner G, Allen SL, Costanza ME, Van Echo DA, Henderson IC, Schilsky RL. Population pharmacodynamic study of amonafide: A Cancer and Leukemia Group B study. *J Clin Oncol* 13, 741-747 (1995).

Ratain Curriculum Vitae – Revised 7/8/2016

67. Larson RA, Geller RB, Janisch L, Suarez D, Milton J, Grochow LB, Ratain MJ. Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies. *Cancer Chemother Pharmacol* 36, 204-210 (1995).
68. Daugherty C, Ratain MJ, Grochowski E, Stocking C, Kodish E, Mick R, Siegler M. Perceptions of cancer patients and their physicians involved in phase I trials. *J Clin Oncol* 13, 1062-1072 (1995).
69. Costanza ME, Berry D, Henderson IC, Ratain MJ, Wu K, Shapiro C, Duggan D, Kalra J, Berkowitz I, Lyss AP. Amonafide: an active agent in the treatment of previously untreated advanced breast cancer: a Cancer and Leukemia Group B study (CALGB 8642). *Clin Cancer Res* 1, 699-704 (1995).
70. Lilenbaum RC, Ratain MJ, Miller AA, Hargis JB, Hollis DR, Rosner GL, O'Brien SM, Brewster L, Graham L, Green MR, Schilsky RL. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a Cancer and Leukemia Group B study. *J Clin Oncol* 13, 2230-2237 (1995).
71. Kobayashi K, Vokes EE, Vogelzang NJ, Janisch L, Soliven B, Ratain MJ. A phase I study of suramin (NSC 34936) given by intermittent infusion without adaptive control in patients with advanced cancer. *J Clin Oncol* 13, 2196-2207 (1995).
72. Gupta E, Olopade OI, Ratain MJ, Mick R, Berezin FK, Benson AB, Dolan ME. Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent. *Clin Cancer Res* 1, 1133-1138 (1995).
73. Kobayashi K, Pezen DS, Vogelzang NJ, Medenica M, Janisch L, Ratain M, Vokes EE, Soltani K. Keratoacanthomas and skin neoplasms associated with suramin. *Arch Dermatol* 132, 96-98 (1996).
74. Ratain MJ, Mick R, Janisch L, Berezin F, Schilsky RL, Vogelzang NJ, Kut M. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. *Pharmacogenetics* 6, 93-101 (1996).
75. Larson RA, Mick R, Spielberger RT, O'Brien SM, Ratain MJ. A dose escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. *J Clin Oncol* 14, 188-195 (1996).
76. Minami H, Beijnen JH, Verweij J, Ratain MJ. Limited sampling model for area under the concentration-time curve of total topotecan. *Clin Cancer Res* 2, 43-46 (1996).
77. Mick R, Vokes EE, Lestingi TM, Gray-Stern W, Fleming GF, Schilsky RL, Ratain MJ. Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics. *Clin Pharmacol Ther* 59, 349-359 (1996).
78. Vokes EE, Mick R, Kies M, Dolan ME, Malone D, Athanasiadis I, Haraf DJ, Kozloff M, Weichselbaum RR, Ratain MJ. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. *J Clin Oncol* 14, 1663-1671 (1996).
79. Gupta E, Safa AR, Wang X, Ratain MJ. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporine A. *Cancer Res* 56, 1309-1314 (1996).
80. Mick R, Gupta E, Vokes EE, Ratain MJ. Limited sampling models for irinotecan (CPT-11) pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. *J Clin Oncol* 14, 2012-2019 (1996).
81. Fleming GF, Janisch L, Vogelzang NJ, Vokes EE, Ratain MJ. Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support. *Cancer* 77, 2308-2312 (1996).
82. Kobayashi K, Weiss RE, Vogelzang NJ, Vokes EE, Janisch L, Ratain MJ. Mineralocorticoid insufficiency due to suramin therapy. *Cancer* 78, 2411-2420 (1996).
83. Minami H, Ratain MJ, Ando Y, Shimokata K. Pharmacodynamic modeling of prolonged administration of etoposide. *Cancer Chemother Pharmacol* 39, 61-66 (1996).

Ratain Curriculum Vitae – Revised 7/8/2016

84. Fleming GF, O'Brien SM, Hoffman PC, Vokes EE, Vogelzang NJ, Schilsky RL, Waggoner SE, Ratain MJ. Phase I study of treatment with oral 13-cisretinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin. *Cancer Chemother Pharmacol* 39, 227-232 (1997).
85. Ramirez J, Ogan K, Ratain MJ. Determination of vinca alkaloids in human plasma by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. *Cancer Chemother Pharmacol* 39, 286-290 (1997).
86. Soliven B, Dhand UK, Kobayashi K, Arora R, Martin B, Petersen M, Janisch L, Vogelzang NJ, Vokes EE, Ratain MJ. Evaluation of neuropathy in patients on suramin treatment. *Muscle Nerve* 20, 83-91 (1997).
87. Gupta E, Wang X, Ramirez J, Ratain MJ. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. *Cancer Chemother Pharmacol* 39, 440-444 (1997).
88. Gupta E, Mick R, Ramirez J, Wang X, Lestingi TM, Vokes EE, Ratain MJ. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan (CPT-11) in cancer patients. *J Clin Oncol* 15, 1502-1510 (1997).
89. Johnston PG, Mick R, Recant W, Behan KA, Dolan ME, Ratain MJ, Beckmann E, Weichselbaum RR, Allegra CJ, Vokes EE. Thymidylate synthase expression predicts for response to neoadjuvant induction chemotherapy in advanced head and neck cancer. *J Natl Cancer Inst* 89, 308-313 (1997).
90. Miller AA, Rosner GL, Ratain MJ, Hollis DR, Green MR, Schilsky RL. Pharmacology of 21-day oral etoposide given in combination with intravenous cisplatin in patients with extensive-stage small-cell lung cancer: a Cancer and Leukemia Group B Study (CALGB 9062). *Clin Cancer Res* 3, 719-725 (1997).
91. Ratain MJ, Skoog LA, O'Brien SM, Cooper N, Schilsky RL, Vogelzang NJ, Gerber M, Narang PK, Nicol SJ. Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl) doxorubicin (FCE 23762, PNU 152243) administered on a daily x 3 schedule. *Ann Oncol* 8, 807-809 (1997).
92. LeMaistre CF, Saleh MN, Kuzel TM, Foss F, Platanius LC, Schwartz G, Ratain MJ, Rook A, Freytes CO, Craig F, Reuben J, Nichols JC. Phase I trial of a ligand fusion-protein (DAB₃₈₉IL-2) in lymphomas expressing the receptor for interleukin-2. *Blood* 91, 399-405 (1998).
93. Mani S, Iyer L, Janisch L, Wang X, Fleming GF, Schilsky RL, Ratain MJ. Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). *Cancer Chemother Pharmacol* 42, 84-87 (1998).
94. Iyer L, King CD, Whittington PF, Green MD, Roy SK, Tephly TR, Ratain MJ. Genetic predisposition to the metabolism of irinotecan (CPT-11): role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. *J Clin Invest* 101, 847-854 (1998).
95. Rini BI, Stadler WM, Spielberger RT, Ratain MJ, Vogelzang NJ. Granulocyte-macrophage colony-stimulating factor (GM-CSF) in metastatic renal cell cancer: a phase II trial. *Cancer* 82, 1352-1358 (1998).
96. Brockstein B, Haraf DJ, Stenson K, Fasanmade A, Stupp R, Glisson B, Lippman SM, Ratain MJ, Sulzen L, Klepsch A, Weichselbaum RR, Vokes EE. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony stimulating factor support for patients with poor-prognosis cancer of the head and neck. *J Clin Oncol* 16, 735-744 (1998).
97. Schilsky RL, Hohnaker J, Ratain MJ, Janisch L, Smetzler L, Lucas VS, Khor SP, Diasio R, Von Hoff DD, Burris HA. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. *J Clin Oncol* 16, 1450-1457 (1998).

Ratain Curriculum Vitae – Revised 7/8/2016

98. Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman DR, Ratain MJ, Kearns CM, Schilsky RL. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. *J Clin Oncol* 16, 1811-1819 (1998).
99. Vogelzang NJ, Mani S, Schilsky RL, Ansari RH, Taber D, Rhinehart SN, Garcia JC, Meyer SC, Mick R, Brockstein BE, Stadler WM, Ratain MJ, Vokes EE. Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in advanced renal and colorectal cancer. *Clin Cancer Res* 4, 929-934 (1998).
100. Dolan ME, Roy SK, Fasanmade AA, Paras PR, Schilsky RL, Ratain MJ. O⁶-benzylguanine in humans: metabolic, pharmacokinetic and pharmacodynamic findings. *J Clin Oncol* 16, 1803-1810 (1998).
101. Fleming GF, Kugler JW, Hoffman PC, Ansari R, Bitran JD, Klepsch A, Malone D, Fasanmade AA, Ratain MJ, Vokes EE. Phase II trial of paclitaxel and topotecan with granulocyte colony stimulating factor support in stage IV breast cancer. *J Clin Oncol* 16, 2032-2037 (1998).
102. Daugherty CK, Ratain MJ, Minami H, Banik DM, Vogelzang NJ, Stadler WM, Siegler M. Study of cohort-specific consent and patient control in phase I cancer trials. *J Clin Oncol* 16, 2305-2312 (1998).
103. Budman DR, Rosner G, Lichtman S, Miller A, Ratain MJ, Schilsky RL. A randomized trial of amifostine as a chemoprotective agent in combination with cyclophosphamide and molgramostim (GM-CSF). *Cancer Ther* 1, 164-167 (1998).
104. Vokes EE, Janisch L, Spector B, Lestingi T, Gupta E, Schilsky RL, Ratain MJ. A phase I dose-intensification study of irinotecan (CPT-11) with maximized supportive care. *Cancer Ther* 1, 223-228 (1998).
105. Lilenbaum RC, Miller AA, Batist G, Bernard S, Hollis DR, Rosner GL, Egorin MJ, Schilsky RL, Ratain MJ. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and Leukemia Group B Study. *J Clin Oncol* 16, 3302-3309 (1998).
106. Vokes EE, Ansari RH, Masters GA, Hoffman PC, Klepsch A, Ratain MJ, Sciortino DF, Lad TE, Krauss S, Fishkin PA, Golomb HM. A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer. *Ann Oncol* 9, 1085-1090 (1998).
107. Saleh MN, LeMaistre CF, Kuzel TM, Foss F, Plataniias LC, Schwartz G, Ratain M, Rook A, Freytes CO, Craig F, Reuben J, Sams MW, Nichols JC. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. *J Am Acad Dermatol* 39, 63-73 (1998).
108. House LK, Ramirez J, Ratain MJ. Simultaneous determination of 5-fluorouracil and uracil by high performance liquid chromatography using four serial columns. *J Chromatogr Biomed Sci Appl* 720, 245-250 (1998).
109. De Mario MD, Ratain MJ, Vogelzang NJ, Mani S, Vokes EE, Fleming GF, Melton K, Johnson S, Benner S, Leibold D. A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days. *Cancer Chemother Pharmacol* 43, 385-388 (1999).
110. Humerickhouse RA, Dolan ME, Haraf DJ, Brockstein B, Stenson K, Kies M, Sulzen L, Ratain MJ, Vokes EE. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. *Clin Cancer Res* 5, 291-298 (1999).
111. Vokes EE, Goh BC, Bertucci D, Vogelzang NJ, Mani S, Ratain MJ. A phase I study of raltitrexed and paclitaxel given every three weeks to patients with solid tumors. *Cancer* 86, 528-532 (1999).

Ratain Curriculum Vitae – Revised 7/8/2016

112. Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S, DiRienzo A, Ratain MJ. Phenotype/genotype correlation of *in vitro* SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. *Clin Pharmacol Ther* 65, 576-582 (1999).
113. Minami H, Lad T, Nicholas MK, Vokes EE, Ratain MJ. Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies. *Clin Cancer Res* 5, 1325-1330 (1999).
114. Brockstein BE, Shepard DR, Kugler JW, Fishkin PA, Arrieta R, Ratain MJ, Vokes EE, Vogelzang NJ. A phase II trial of oral trimethylcolchicinic acid in patients with hormone refractory prostate cancer. *Prostate J* 1, 195-202 (1999).
115. Daugherty CK, Banik DM, Janisch L, Ratain MJ. Quantitative analysis of ethical issues in phase I trials: a survey interview study of 144 advanced cancer patients. *IRB* 22, 6-14 (2000).
116. Goh BC, Fleming GF, Janisch L, Vogelzang NJ, Stadler WM, Ratain MJ. Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations. *Cancer Chemother Pharmacol* 45, 489-494 (2000).
117. Ryan CW, Fleming GF, Janisch L, Ratain MJ. A phase I study of liposomal doxorubicin (Doxil[®]) with topotecan. *Am J Clin Oncol* 23, 297-300 (2000).
118. Schilsky RL, Dolan ME, Bertucci D, Ewesuedo RB, Vogelzang NJ, Mani S, Wilson LR, Ratain MJ. Phase I clinical and pharmacological study of O⁶-benzylguanine followed by carmustine in patients with advanced cancer. *Clin Cancer Res* 6, 3025-3031 (2000).
119. Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. *J Clin Oncol* 18, 2780-2787 (2000).
120. Innocenti F, Stadler WM, Iyer L, Ramirez J, Vokes EE, Ratain MJ. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. *Clin Cancer Res* 6, 3400-3405 (2000).
121. Benson AB, Olopade OI, Ratain MJ, Rademaker A, Mobarhan S, Stucky-Marshall L, French S, Dolan ME. Chronic daily low dose of 4-methyl-5 (2-pyrazinyl)-1,2 dithiole-3-thione (oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients. *Clin Cancer Res* 6, 3870-3877 (2000).
122. Joshi AS, Pieniaszek HJ Jr, Vokes EE, Vogelzang NJ, Davidson AF, Richards LE, Chai MF, Finizio M, Ratain MJ. Elimination pathways of [¹⁴C]losoxantrone in four cancer patients. *Drug Metab Disp* 29, 96-99 (2001).
123. Goh BC, Ratain MJ, Bertucci D, Smith R, Mani S, Vogelzang NJ, Schilsky RL, Hutchison M, Smith M, Averbuch S, Douglass E. Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. *J Clin Oncol* 19, 1476-1484 (2001).
124. Ewesuedo RB, Iyer L, Das S, Koenig A, Mani S, Vogelzang NJ, Schilsky RL, Brenckman W, Ratain MJ. Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer. *J Clin Oncol* 19, 2084-2090 (2001).
125. Rudin CM, Holmlund J, Fleming GF, Mani S, Stadler WM, Dorr FA, Ratain MJ, Schumm P, Monia BP, Johnston JF, Geary R, Yu RZ, Kwoh TJ. Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of *c-Raf-1*, administered by 24-hour weekly infusion to patients with advanced cancer. *Clin Cancer Res* 7, 1214-1220 (2001).
126. Innocenti F, Iyer L, Ramirez J, Green MD, Ratain MJ. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. *Drug Metab Disp* 29, 686-692 (2001).

Ratain Curriculum Vitae – Revised 7/8/2016

127. Mani S, Vogelzang NJ, Bertucci D, Stadler WM, Schilsky RL, Ratain MJ. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. *Cancer* 92, 1567-1576 (2001).
128. Eng C, Mauer AM, Fleming GF, Bertucci D, Rotmensch J, Jacobs RH, Ratain MJ. Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors. *Ann Oncol* 12, 1743-1747 (2001).
129. Schilsky RL, Bertucci D, Vogelzang NJ, Kindler HL, Ratain MJ. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. *J Clin Oncol* 20, 582-587 (2002).
130. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ. *UGT1A1*28* polymorphism as a determinant of irinotecan disposition and toxicity. *Pharmacogenomics J* 2, 43-47 (2002).
131. Goh BC, Vokes EE, Joshi A, Ratain MJ. Phase I study of the combination of Iloxantrone and cyclophosphamide in patients with refractory solid tumors. *Br J Cancer* 86, 534-539 (2002).
132. Iyer L, Ramirez J, Shepard DR, Bingham C, Hossfeld DK, Ratain MJ, Mayer U. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein deficient mice. *Cancer Chemotherapy Pharmacol* 49, 336-361 (2002).
133. Mani S, Rudin CM, Kunkel K, Holmlund JT, Geary RS, Kindler HL, Dorr FA, Ratain MJ. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. *Clin Cancer Res* 8, 1042-1048 (2002).
134. Shepard DR, Mani S, Kastrissos H, Learned-Coughlin S, Smith D, Ertel P, Magnum S, Janisch L, Fleming GF, Schilsky RL, Ratain MJ. Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. *Cancer Chemother Pharmacol* 49, 398-402 (2002).
135. Ramirez J, Iyer L, Journault K, Belanger P, Innocenti F, Ratain MJ, Guillemette C. In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. *Pharmaceut Res* 19, 588-594 (2002).
136. Ryan CW, Vokes EE, Vogelzang NJ, Janisch L, Kobayaski K, Ratain MJ. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer. *Cancer Chemother Pharmacol* 50, 1-5 (2002).
137. Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of Intergroup 0159, Cancer and Leukemia Group B 9480. *J Clin Oncol* 20, 3369-3375 (2002).
138. Lathia C, Fleming GF, Meyer M, Ratain MJ, Whitfield L. Pentostatin pharmacokinetics and dosing guidelines in patients with mild renal impairment. *Cancer Chemother Pharmacol* 50, 121-126 (2002).
139. Dolan ME, Posner M, Karrison T, Radosta J, Steinberg G, Bertucci D, Vujasin L, Ratain MJ. Determination of the optimal modulatory dose of O⁶-benzylguanine in patients with surgically resectable tumors. *Clin Cancer Res* 8, 2519-2523 (2002).
140. Rosner GL, Stadler W, Ratain MJ. The randomized discontinuation design: application to cytostatic antineoplastic agents. *J Clin Oncol* 20, 4478-4484 (2002).
141. Fleming GF, Meropol NJ, Rosner GL, Hollis DR, Carson WE, Caligiuri M, Mortimer J, Tkaczuk K, Parihar R, Schilsky RL, Ratain MJ. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin-2: report of Cancer and Leukemia Group B 9661. *Clin Cancer Res* 8, 3718-3727 (2002).

Ratain Curriculum Vitae – Revised 7/8/2016

142. Klein CE, Gupta E, Reid JM, Pitot HC, Ratain MJ, Kastrissios H. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. *Clin Pharmacol Ther* 72, 638-647 (2002).
143. Innocenti F, Grimsley C, Das S, Ramirez J, Cheng C, Kuttab-Boulos H, Ratain MJ, DiRienzo A. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. *Pharmacogenetics* 12, 725-733 (2002).
144. Liu W, Innocenti F, Das S, Chen P, Cook EH, Ratain MJ. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. *Clin Cancer Res* 9, 1009-1012 (2003).
145. Sawyer MB, Ratain MJ, Bertucci D, Smith RP, Schilsky, RL, Vogelzang NJ, Shulman K, Douglass EC, Fleming GF. Phase I study of an oral formulation of ZD9331 administered daily for 28 days. *J Clin Oncol* 21, 1859-1865 (2003).
146. Sawyer MB, Innocenti F, Das S, Cheng C, Ramirez J, Pantle-Fisher FH, Wright C, Pei D, Boyett JM, Cook E, Ratain MJ. A pharmacogenetic study of UDP-glucuronosyltransferase 2B7 in patients receiving morphine. *Clin Pharmacol Ther* 73, 566-574 (2003).
147. Masters GA, Brockstein BE, Mani S, Ratain MJ. Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors. *Med Oncol* 20, 7-12 (2003).
148. Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR. Weekly, high-dose paclitaxel in advanced lung cancer: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. *Cancer* 97, 2480-2486 (2003).
149. Fleming GF, Schilsky RL, Schumm LP, Meyerson A, Hong AM, Vogelzang NJ, Ratain MJ. Phase I and pharmacokinetic study of 24-hour infusion of 5-fluorouracil and leucovorin in patients with organ dysfunction. *Ann Oncol* 14, 1142-1147 (2003).
150. Venook AP, Klein CE, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona-Calero M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. *Ann Oncol* 14, 1783-1790 (2003).
151. Kimmick G, Ratain MJ, Berry D, Woolf S, Norton L, Muss HB. Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041). *Invest New Drug* 22, 83-89 (2004).
152. Innocenti F, Undevia SD, Iyer L, Chen P, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. *J Clin Oncol* 22, 1382-1388 (2004).
153. Undevia SD, Vogelzang NJ, Mauer AM, Janisch L, Mani S, Ratain MJ. Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. *Invest New Drugs* 22, 449-458 (2004).
154. Vogelzang NJ, Karrison T, Stadler WM, Garcia J, Cohn H, Kugler J, Troeger T, Giannone L, Arrieta R, Ratain MJ, Vokes EE. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate cancer. *Cancer* 100, 65-71 (2004).
155. Meyerhardt JA, Kwok A, Ratain MJ, McGovern JP, Fuchs CS. Analysis of relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. *J Clin Oncol* 22, 1439-1446 (2004).
156. Odenike OM, Sobecks RM, Janisch L, Huo D, Zimmerman TM, Daugherty CK, Ratain MJ, Larson RA. A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. *Cancer Chemother Pharmacol* 54, 553-561(2004).

Ratain Curriculum Vitae – Revised 7/8/2016

157. Desai AA, Innocenti F, DeMario M, Shepard D, Ramirez J, Fleming G, Ratain MJ. A phase I trial of pharmacokinetic modulation of carboxyamido-triazole (CAI) with ketoconazole in advanced cancer patients. *Cancer Chemother Pharmacol* 54, 377-384 (2004).
158. Ramirez J, Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, Ratain MJ. CYP2B6 and CYP3A4 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. *Drug Metab Disp* 32, 930-936 (2004).
159. Dolan ME, Newbold KG, Nagasubramnian R, Wu X, Ratain MJ, Cook EH, Badner JA. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. *Cancer Res* 64, 4353-4536 (2004).
160. Ryan CW, Vogelzang NJ, Vokes EE, Kindler HL, Undevia SD, Humerickhouse R, Andre AK, Wang O, Carr RA, Ratain MJ. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. *Clin Cancer Res* 10, 4406-4411 (2004).
161. Rudin CM, Marshall J, Huang CH, Kindler HL, Zhang C, Kumar D, Gokhale PC, Steinberg J, Wanasaki S, Kasid VN, Ratain MJ. Delivery of a liposomal C-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. *Clin Cancer Res* 10, 7244-7251 (2004).
162. Undevia SD, Kindler HL, Janisch L, Olson C, Schilsky RL, Vogelzang NJ, Macek TA, Ratain MJ. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. *Ann Oncol* 15, 1705-1711(2004).
163. Helft PR, Schilsky RL, Hoke FJ, Kindler HL, Sprague E, DeWitte M, Martino HK, Erickson J, Pandite L, Russo M, Lambert JM, Howard M, Ratain MJ. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. *Clin Cancer Res* 10, 4363-4368 (2004).
164. Innocenti F, Undevia SD, Ramirez J, Mani S, Schilsky RL, Vogelzang NJ, Prado M, Ratain MJ. A phase I trial of pharmacological modulation of irinotecan with cyclosporine and phenobarbital. *Clin Pharmacol Ther* 76, 490-502 (2004).
165. Miller AA, Rosner GL, Egorin MJ, Hollis D, Lichtman SM, Ratain MJ. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors. *Cancer and Leukemia Group B (CALGB) study 9763*. *Clin Cancer Res* 10, 8325-8331 (2004).
166. Ahles TA, Herndon JE, Small EJ, Vogelzang NJ, Kornblith AB, Ratain MJ, Stadler W, Palchak D, Marshall ME, Wilding G, Petrylak D, Holland JC. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate cancer. *Cancer* 101, 2202-2208 (2004).
167. Zimmerman TM, Harlin H, Odenike OM, Berk S, Sprague E, Karrison T, Stock W, Larson RA, Ratain MJ, Gajewski TF. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. *J Clin Oncol* 22, 4816-4822 (2004).
168. Liu W, Innocenti F, Wu MH, Desai A, Dolan ME, Cook EH, Ratain MJ. A functional common polymorphism in an Sp1 recognition site of the epidermal growth factor receptor promoter. *Cancer Res* 65, 46-53 (2005).
169. Marshall JL, Kindler H, Deeken J, Bhargava P, Vogelzang NJ, Rizvi N, Luhtala T, Boylan S, Dordal M, Robertson P, Hawkins MJ, Ratain MJ. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. *Invest New Drugs* 23, 31-37 (2005).
170. Desai AA, Schilsky RL, Young A, Janisch L, Stadler WM, Vogelzang NJ, Cadden S, Wright JA, Ratain MJ. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors and lymphoma. *Ann Oncol* 16, 958-965 (2005).

Ratain Curriculum Vitae – Revised 7/8/2016

171. Innocenti F, Liu W, Chen P, Desai AA, Das S, Ratain MJ. Haplotypes of variants in the UDP-glucuronosyltransferase 1A9 and 1A1 genes. *Pharmacogenet Genomics* 15, 295-301 (2005).
172. Stadler WM, Rosner G, Small E, Hollis D, Rini B, Zaantz SD, Mahoney J, Ratain MJ. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyamidotriazole in renal cell carcinoma. *J Clin Oncol* 23, 3726-3732 (2005).
173. Desai AA, Kindler HL, Taber D, Agamah E, Mani S, Wade-Oliver K, Ratain MJ, Vokes EE. Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer. *Cancer Chemother Pharmacol* 54, 421-426 (2005).
174. French D, Wilkinson MR, Yang W, de Chaisemartin L, Cook EH, Das S, Ratain MJ, Evans WE, Downing JR, Pui, CH, Relling MV. Global gene expression as a function of germline genetic variation. *Hum Mol Genet* 14, 1621-1629 (2005).
175. Klein CE, Kastrissios H, Miller AA, Hollis D, Yu D, Rosner G, Grinblatt DL, Larson RA, Ratain MJ. Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: A Cancer and Leukemia Group B study. *Cancer Chemother Pharmacol* 13, 1-8 (2005).
176. Yong WP, Ramirez J, Innocenti F, Ratain MJ. Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. *Clin Cancer Res* 11, 6669-6704 (2005).
177. Ramirez J, Komoroski BJ, Mirkov S, Graber AY, Fackenthal DL, Schuetz EG, Das S, Ratain MJ, Innocenti F, Strom SC. Study of the genetic determinants of *UGT1A1* inducibility by phenobarbital in cultured human hepatocytes. *Pharmacogenet Genomics* 16, 79-86 (2006).
178. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ. A phase II, placebo-controlled, randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. *J Clin Oncol* 24, 2505-2512 (2006).
179. Lichtman SM, Hollis D, Miller AA, Rosner GL, Rhoades CA, Lester EP, Millard F, Byrd J, Cullinan SA, Rosen DM, Parise RA, Ratain MJ, Egorin MJ. Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). *J Clin Oncol* 24, 1846-1851 (2006).
180. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O'Dwyer PJ, Ratain MJ. Sorafenib in advanced melanoma: a phase II randomized discontinuation analysis. *Br J Cancer* 95, 581-586 (2006).
181. Lacouture ME, Desai A, Soltani K, Rosic K, Laumann AE, Ratain MJ, Stadler WM. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multi-targeted tyrosine-kinase inhibitor. *Clin Exp Dermatol* 31, 783-785 (2006).
182. Ramchandani RP, Wang Y, Booth BP, Ibrahim A, Johnson JR, Rahman A, Mehta M, Innocenti F, Ratain MJ, Gobburu JV. The role of SN-38 exposure, *UGT1A1*28* polymorphism and baseline bilirubin level in predicting severe irinotecan toxicity. *J Clin Pharmacol* 47, 78-86 (2007).
183. Graber AY, Ramirez J, Zhang W, Innocenti F, Ratain MJ. *UGT1A1*28* genotype affects the in-vitro glucuronidation of thyroxine in human livers. *Pharmacogenet Genomics* 17, 619-627 (2007).
184. Mirkov S, Komoroski BJ, Ramirez J, Graber AY, Ratain MJ, Strom SC, Innocenti F. Effects of green tea compounds on irinotecan metabolism. *Drug Metab Dispos* 35, 228-233 (2007).
185. Michaelis LC, Ratain MJ. Phase II trials published in 2002: A cross-specialty comparison demonstrating significant differences between oncology trials and other medical specialties. *Clin Cancer Res* 13, 2400-2405 (2007).

Ratain Curriculum Vitae – Revised 7/8/2016

186. Hlubocky FJ, Ratain MJ, Wen M, Daugherty CK. Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making. *J Clin Oncol* 25, 548-554 (2007).
187. Otterson GA, Villalona-Calero MA, Sharma S, Kris MG, Imondi A, Gerber M, White DA, Ratain MJ, Schiller JH, Sandler A, Kraut M, Mani S, Murren JR. Phase I study of inhaled doxorubicin for patients with metastatic tumors to the lungs. *Clin Cancer Res* 13, 1246-1252 (2007).
188. Lewis LD, Miller AA, Rosner GL, Dowell JE, Valdivieso M, Relling MV, Egorin MJ, Bies RR, Hollis DR, Levine E, Otterson GA, Millard F, Ratain MJ. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. *Clin Cancer Res* 13, 3302-3311 (2007).
189. Yong WP, Desai AA, Innocenti F, Ramirez J, Shepard D, Kobayashi K, House L, Fleming GF, Vogelzang NJ, Schilsky RL, Ratain MJ. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. *Cancer Chemother Pharmacol*, 60, 811-819 (2007).
190. Zhang W, Liu W, Innocenti F, Ratain MJ. Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms. *PLoS ONE* 2, e396 (2007).
191. Miller AA, Murry DJ, Owzar K, Hollis DR, Lewis LD, Kindler HL, Marshall JL, Villalona-Calero MA, Edelman MJ, Hohl RJ, Lichtman SM, Ratain MJ. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B Study 60101. *J Clin Oncol* 25, 3055-3060 (2007).
192. Gray SW, Hlubocky F, Ratain MJ, Daugherty CK. Attitudes towards research participation and investigator conflicts of interests among advanced cancer patients participating in early phase clinical trials. *J Clin Oncol* 25, 3488-3494 (2007).
193. Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancer. *J Natl Cancer Inst* 99, 1455-1461 (2007).
194. Ramirez J, Liu W, Mirkov S, Desai AA, Chen P, Das S, Innocenti F, Ratain MJ. Lack of association between common polymorphisms in *UGT1A9* and gene expression and activity. *Drug Metab Dispos* 35, 2149-2153 (2007).
195. Liu W, Wu X, Zhang W, Montenegro RC, Fackenthal DL, Spitz JA, Huff LM, Innocenti F, Das S, Cook EH, Cox NJ, Bates SE, Ratain MJ. EGFR mutations, expression, amplification, polymorphisms and their interrelationship with sensitivity/resistance to EGFR inhibitors in the NCI60 cell lines. *Clin Cancer Res* 15, 6788-6795 (2007).
196. Ramirez J, Mirkov S, Zhang W, Chen P, Das S, Liu W, Ratain MJ, Innocenti F. Hepatocyte nuclear factor -1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver. *Pharmacogenomics J* 8, 152-161 (2008).
197. Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, Fackenthal DL, Chen P, Armstrong DK, Brahmer JR, Fogle M, Fleming GF, Vokes EE, Carducci MA, Ratain MJ. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. *J Clin Oncol* 26, 1119-1127 (2008).
198. Schilsky RL, Geary D, Skoog L, Desai A, Valickas J, Chen BL, Masson E, Laurent D, Pendowski C, Vokes EE, Ratain MJ. Phase I and pharmacokinetic study of vatalanib and capecitabine in patients with advanced cancer. *Targeted Oncology* 3, 3-11 (2008).
199. Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, Desai AA, Singleton PA, Sammani S, Sam L, Liu Y, Husain A, Lang RM, Ratain MJ, Lussier YA, Garcia JG. Genomic assessment of a multi-kinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. *Physiol Genomics* 22, 278-291 (2008).

Ratain Curriculum Vitae – Revised 7/8/2016

200. Odenike OM, Larson RA, Gajria D, Dolan ME, Delaney S, Karrison TG, Ratain MJ, Stock W. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone, in combination with high dose cytarabine in patients with advanced myeloid leukemia. *Invest New Drugs* 26, 233-239 (2008).
201. Rosner GL, Panetta JC, Innocenti F, Ratain MJ. Pharmacogenetic pathway analysis of irinotecan. *Clin Pharmacol Ther* 84, 393-402 (2008).
202. Stock W, Undevia S, Ravandi F, Odenike T, Faderl S, Rich E, Borthakur G, Godley L, Verstovsek S, Artz A, Wierda W, Larson RA, Cortes J, Ratain MJ, Giles FJ. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory leukemia. *Invest New Drugs* 26, 331-338 (2008).
203. Innocenti F, Liu W, Fackenthal D, Ramirez J, Chen P, Ye X, Wu X, Zhang W, Mirkov S, Das S, Cook E, Ratain MJ. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene. *Pharmacogenet Genomics* 18, 683-697 (2008).
204. Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ, Stadler WM. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal cell carcinoma. *J Clin Oncol* 26, 4572-4578 (2008).
205. Undevia SD, Innocenti F, Ramirez J, House L, Desai AA, Skoog LA, Singh DA, Karrison T, Kindler HL, Ratain MJ. A phase I and pharmacokinetic study of the quinoxaline antitumor agent R(+)-XK469 in patients with advanced solid tumors. *Eur J Cancer* 44, 1684-1692 (2008).
206. Zhang W, Liu W, Poradosu E, Ratain MJ. Genome-wide identification of genetic determinants for the cytotoxicity of perifosine. *Hum Genomics* 3, 53-70 (2008).
207. Bartlett NL, Johnson JL, Wagner-Johnston N, Ratain MJ, Peterson BA. Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551. *Cancer Chemother Pharmacol* 63, 793-798 (2009).
208. Innocenti F, Mirkov S, Nagasubramanian R, Ramirez J, Liu W, Bleibel WK, Shukla SJ, Hennessy K, Rosner GL, Cook E, Dolan ME, Ratain MJ. The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds. *Cancer Chemother Pharmacol* 63, 881-887 (2009).
209. Perera MA, Thirumaran RK, Cox NJ, Hanauer S, Das S, Brimer-Cline C, Lamba V, Schuetz EG, Ratain MJ, Di Rienzo A. Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans. *Pharmacogenomics J* 9, 49-60 (2009).
210. Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, Loewy JW, Kindler H, Stadler WM, Knowles HL, Bedrosian C, Ratain MJ. A phase I trial to determine the safety, tolerability, and maximally tolerated dose of deforolimus (AP23573) an mTOR inhibitor in patients with advanced malignancies. *Clin Cancer Res* 15, 1428-1434 (2009).
211. Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa-G, Desai A, Hwang J, Villalona-Calero MA, Dees EC, Lewis LD, Fakhri MG, Edelman MJ, Millard F, Frank RC, Hohl RJ, Ratain MJ. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B study 60301. *J Clin Oncol* 27, 1800-1805 (2009).
212. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramirez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. *J Clin Oncol* 27, 2604-2614 (2009).
213. Zhang W, He L, Liu W, Sun C, Ratain MJ. Exploring the relationship between polymorphic (TG/CA)_n repeats in intron 1 regions and gene expression. *Hum Genomics* 3, 236-245 (2009).
214. Hoskins JM, Rosner GL, Ratain MJ, McLeod HM, Innocenti F. Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. *Pharmacogenomics* 10, 1139-1146 (2009).

Ratain Curriculum Vitae – Revised 7/8/2016

215. Yong WP, Kim TW, Undevia SD, Innocenti F, Ratain MJ. R(+)-XK469 inhibits hydroxylation of S-warfarin by CYP2C9. *Eur J Cancer* 45, 1904-1908 (2009).
216. Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, Undevia SU, Stadler WL, Elliott WJ, Ratain MJ. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. *Clin Cancer Res* 15, 6250-6257 (2009).
217. Zhang W, Catenacci DV, Duan S, Ratain MJ. A survey of the population genetic variation in the human kinome. *J Hum Genetic* 54, 488-492 (2009).
218. Liu W, He L, Ramirez J, Ratain MJ. Interactions between MDM2 and TP53 alterations, and their impact on response to MDM2 inhibitors and other chemotherapeutic drugs in cancer cells. *Clin Cancer Res* 15, 7602-7607 (2009).
219. Gomberg-Maitland M, Maitland ML, Barst RJ, Sugeng L, Coslet S, Perrino TJ, Bond L, LaCouture ME, Archer SL, Ratain MJ. A dosing/cross-development study of the multi-kinase inhibitor sorafenib in pulmonary arterial hypertension patients. *Clin Pharmacol Ther* 87, 303-310 (2010).
220. Liu Y, Ramirez J, House L, Ratain MJ. Comparison of the drug-drug interaction potentials of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. *Drug Metab Disp* 38, 32-39 (2010).
221. Liu Y, Ramirez J, House L, Ratain MJ. The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation. *Eur J Cancer* 46, 2097-2103 (2010).
222. Kang SP, Ratain MJ. Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products. *Clin Cancer Res* 16, 4446-4451 (2010).
223. Kang SP, Ramirez J, House L, Zhang W, Mirkov S, Liu W, Haverfield E, Ratain MJ. A pharmacogenetic study of vorinostat glucuronidation. *Pharmacogenet Genomics* 20, 638-641 (2010).
224. Hamberg P, Ratain MJ, Lesaffre E, Verweij J. Dose-escalation models for combination phase I trials in oncology. *Eur J Cancer* 46, 2870-2878 (2010).
225. Kamdem LK, Liu Y, Stearns V, Kadlubar SA, Ward B, Ogburn E, Ramirez J, Mirkov S, Ratain MJ, Flockhart DA, Desta Z. In vitro and in vivo phase I and II metabolism of anastrozole. *Br J Clin Pharmacol* 70, 854-869 (2010).
226. Maitland ML, Hudoba C, Snider KL, Ratain MJ. Analysis of the yield of phase II combination trials in medical oncology. *Clin Cancer Res* 16, 5296-5302 (2010).
227. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SHI, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan WW, Gandhi L, Mino-Kenudsen M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. *New Engl J Med* 363, 1693-1703 (2010).
228. Pacey S, Ratain MJ, Flaherty KT, Kaye SB, Cupit L, Rowinsky EK, Xia C, O'Dwyer PJ, Judson IR. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. *Invest New Drugs* 29, 481-488 (2011).
229. Liu Y, Ramirez J, Ratain MJ. Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. *Br J Clin Pharmacol* 71, 917-920 (2011).
230. Kurzrock R, Sherman SI, Ball D, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EEW, Janisch L, Nauling F, Hong DS, Ng C, Lei Y, Gagel RF, Frye J, Muller T, Ratain MJ, Salgia R. Activity of XL184, an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. *J Clin Oncol* 29, 2660-2666 (2011).

Ratain Curriculum Vitae – Revised 7/8/2016

231. Gangadhar T, Cohen EE, Wu K, Janisch L, Geary D, Kocherginsky M, House LK, Ramirez J, Undevia SD, Maitland ML, Fleming GF, Ratain MJ. Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. *Clin Cancer Res* 17, 1956-1963 (2011).
232. Liu W, He L, Ramirez J, Krishnaswamy S, Kanteti R, Wang YC, Salgia R, Ratain MJ. Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer with a predominant effect on exon 19 microdeletions. *Cancer Res* 71, 2423-2427 (2011).
233. Cohen EE, Sharma MR, Janisch L, Llobrera M, House L, Wu K, Ramirez J, Fleming GF, Stadler WM, Ratain MJ. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. *Eur J Cancer* 47, 1484-1489 (2011).
234. Innocenti F, Cooper GM, Stanaway IB, Gamazon ER, Smith JD, Mirkov S, Ramirez J, Liu W, Lin YS, Moloney C, Aldred SF, Trinklein ND, Schuetz E, Nickerson DA, Thummel KE, Rieder MJ, Rettie AE, Ratain MJ, Cox NJ, Brown CD. Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. *PLOS Genet* 7, e1002078 (2011).
235. Ramirez J, Wu K, Janisch L, Karrison T, House LK, Innocenti F, Cohen EEW, Ratain MJ. The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients. *Cancer Chemother Pharmacol* 68, 1629-1632 (2011).
236. O'Donnell PH, Undevia SD, Stadler WM, Karrison TM, Nicholas MK, Janisch L, Ratain MJ. A phase I study of continuous infusion cilengitide in patients with solid tumors. *Invest New Drugs* 30, 604-610 (2012).
237. Innocenti F, Owzar K, Cox NL, Evans P, Kubo M, Zembutsu H, Jiang C, Hollis D, Mushiroda T, Li L, Friedman P, Wang L, Glubb D, Hurwitz H, Giacomini KM, McLeod HL, Goldberg RM, Schilsky RL, Kindler HL, Nakamura Y, Ratain MJ. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. *Clin Cancer Res* 18, 577-584 (2012).
238. Sharma MR, Karrison TG, Jin Y, Bies RR, Maitland ML, Stadler WM, Ratain MJ. Resampling phase III data to assess phase II trial designs and endpoints. *Clin Cancer Res* 18, 2309-2315 (2012).
239. Cohen EEW, Wu K, Hartford C, Kocherginsky M, Eaton KN, Zha Y, Nallari A, Maitland ML, Fox-Kay K, Moshier K, House L, Ramirez J, Undevia SD, Fleming GF, Gajewski TF, Ratain MJ. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. *Clin Cancer Res* 18, 4785-4793 (2012).
240. Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis C, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. *Clin Cancer Res* 18, 5099-5109 (2012).
241. Wu K, Cohen EEW, House LK, Ramirez J, Zhang W, Ratain MJ, Bies RR. Nonlinear population pharmacokinetics of sirolimus in cancer patients. *CPT Pharmacometrics Syst Pharmacol* 1, e17 (2012).
242. de Souza JA, Polite B, Perkins M, Meropol NJ, Ratain MJ, Newcomer LN, Alexander GC. Unsupported off-label chemotherapy in metastatic colon cancer. *BMC Health Serv Res* 12, 481 (2012).
243. Karrison T, Ratain MJ, Stadler WM, Rosner GL. Estimation of progression-free survival for all patients in the randomized discontinuation trial design. *Am Stat* 66, 155-162 (2012).

Ratain Curriculum Vitae – Revised 7/8/2016

244. Lewis LD, Miller AA, Owzar K, Bies RR, Markova S, Jiang C, Kroetz DL, Egorin MJ, McLeod HL, Ratain MJ. The relationship of polymorphisms in ABCC2 and SLCO1B3 to docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). *Pharmacogenet Genomics* 23, 29-33 (2013).
245. Wheeler HE, Gamazon ER, Wing C, Njaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman L, Ratain MJ, Kroetz D, Cox NJ, Dolan ME. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of paclitaxel-induced sensory neuropathy. *Clin Cancer Res* 19, 491-499 (2013).
246. Nguyen TD, Markova S, Liu W, Gow JM, Baldwin RM, Habashian M, Relling MV, Ratain MJ, Kroetz DL. Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression. *Pharmacogenomics J* 13, 396-402 (2013).
247. Maitland ML, Wu K, Sharma MR, Jin Y, Kang SP, Stadler WM, Karrison TG, Ratain MJ, Bies RR. Estimation of renal cell carcinoma treatment effects from disease progression modeling. *Clin Pharmacol Ther* 93, 345-351 (2013).
248. Wang LZ, Ramirez J, Yeo W, Chan MY, Thuya WL, Lau JY, Wan SC, Wong AL, Zee YK, Lim R, Lee SC, Ho PC, Lee HS, Chan A, Ansher S, Ratain MJ, Goh BC. Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. *PLoS One* 8, e54522 (2013).
249. Sharma MR, Karrison TG, Kell B, Wu K, Turcich M, Geary D, Kang SP, Takebe N, Graham RA, Maitland ML, Schilsky RL, Ratain MJ, Cohen EE. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. *Clin Cancer Res* 19, 3059-3067 (2013).
250. Innocenti F, Ramirez J, Obel J, Xiong J, Mirkov S, Chiu YL, Katz DA, Carr RA, Zhang W, Das S, Adjei A, Moyer AM, Chen PX, Krivoschik A, Medina D, Gordon GB, Ratain MJ, Sahelijo L, Weinshilboum RM, Fleming GF, Bhathena A. Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. *Pharmacogenet Genomics* 23, 374-381 (2013).
251. Kitano S, Myers J, Nakamura J, Yamane A, Yamashita M, Nakayama M, Tsukahara Y, Ushida H, Liu W, Ratain MJ, Amano M. A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection. *PLOS One* 8, e62989 (2013).
252. Gamazon ER, Innocenti F, Wei R, Wang L, Zhang M, Mirkov S, Ramirez J, Huang RS, Cox NJ, Ratain MJ, Liu W. A genome-wide integrative study of microRNAs in liver. *BMC Genomics* 14, 395 (2013).
253. Bhatta SS, Wroblewski KE, Agarwal KL, Sit L, Cohen EEW, Seiwert TY, Karrison T, Bakris GL, Ratain MJ, Vokes EE, Maitland ML. Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. *Oncologist* 18, 965-970 (2013).
254. O'Brien VP, Bokelmann K, Ramirez J, Jobst K, Ratain MJ, Brockmoller J, Tzvetkov MV. Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter OCT1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene. *J Pharmacol Exp Ther* 347, 181-192 (2013).
255. Wu K, House L, Ramirez J, Seminerio MJ, Ratain MJ. Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs. *Clin Cancer Res* 19, 6039-6043 (2013).
256. Wang J, Carvajal-Carmona LG, Chu JH, Zauber AG, Collaborators AT, Kubo M, Matsuda K, Dunlop M, Houlston RS, Sieber OM, Lipton L, Gibbs P, Martin NG, Montgomery GW, Young JP, Baird PN, Ratain MJ, Nakamura Y, Weiss S, Tomlinson I, Bertagnolli MM. Germline variants and advanced colorectal adenomas: Adenoma Prevention with Celecoxib Prevention Trial genomewide association study. *Clin Cancer Res* 19, 6430-6437 (2013).
257. Ramirez J, Kim TW, Liu W, Myers JL, Mirkov S, Owzar K, Watson D, Mulkey F, Gamazon ER, Stock W, Undevia S, Innocenti F, Ratain MJ. A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. *Pharmacogenet Genomics* 24, 129-132 (2014).

Ratain Curriculum Vitae – Revised 7/8/2016

258. Salgia R, Patel P, Bothos J, Yu W, Eppler S, Hegde P, Bai S, Kaur S, Nijem I, Catenacci DV, Peterson A, Ratain MJ, Polite BN, Mehnert JM, Moss R. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. *Clin Cancer Res* 20, 1666-1675 (2014).
259. Chhibber A, Mefford J, Stahl EA, Pendergrass SA, Baldwin RM, Owzar K, Li M, Winer EP, Hudis CA, Zembutsu H, Kubo M, Nakamura Y, McLeod HL, Ratain MJ, Shulman LN, Ritchie MD, Plenge RM, Witte JS, Kroetz DL. Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101. *Pharmacogenomics J* 14, 336-342 (2014).
260. O'Donnell PH, Danahey K, Wadhwa NR, Jacobs M, Yuen S, Bush A, Sacro Y, Sorrentino MJ, Siegler M, Harper W, Warrick A, Das S, Saner D, Corless CL, Ratain MJ. Adoption of a clinical pharmacogenomics implementation program during outpatient care – initial results of The University of Chicago '1200 Patients Project'. *Am J Med Genet C Semin Med Genet* 166, 68-75 (2014).
261. Elez ME, Taberner J, Geary D, Macarulla T, Kang SP, Kahatt C, Pita AS, Teruel CF, Siguero M, Cullell-Young M, Szyldergemajn S, Ratain MJ. First-in-human phase I study of lurbinectidin (PM01183) in patients with advanced solid tumors. *Clin Cancer Res* 20, 2205-2214 (2014).
262. Karovic S, Wen Y, Karrison TG, Bakris GL, Levine MR, House LK, Wu K, Thomeas V, Rudek MA, Wright JJ, Cohen EE, Fleming GF, Ratain MJ, Maitland ML. Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. *Clin Pharmacol Ther* 96, 27-35 (2014).
263. Innocenti F, Schilsky RL, Ramirez J, Janisch L, Undevia S, House LK, Das S, Wu K, Turcich M, Marsh R, Karrison T, Maitland ML, Salgia R, Ratain MJ. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. *J Clin Oncol* 32, 2328-2334 (2014).
264. de Souza JA, Yap B, Hlubocky F, Wroblewski K, Ratain MJ, Cella D, Daugherty C. The development of a financial toxicity patient reported outcome in cancer: the COST measure. *Cancer* 120, 3245-3253 (2014).
265. Wang X, Owzar K, Gupta P, Larson RA, Mulkey F, Miller AA, Lewis LD, Hurd D, Vij R, Ratain MJ, Murry DJ. Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). *Br J Clin Pharmacol* 78, 1005-1013 (2014).
266. Liu W, Ramirez J, Gamazon ER, Mirkov S, Chen P, Wu K, Sun C, Cox NJ, Cook E, Das S, Ratain MJ. Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver. *Hum Mol Genet* 23, 5558-5569 (2014).
267. Fang H, Liu X, Ramirez J, Choudhury N, Kubo M, Im HK, Konkashbaev A, Cox NJ, Ratain MJ, Nakamura Y, O'Donnell PH. Establishment of CYP2D6 reference samples by multiple validated genotyping platforms. *Pharmacogenomics J* 14, 564-572 (2014).
268. Wu K, Gamazon ER, Im HK, Geeleher P, White S, Solway J, Weiss ST, Tantisira K, Cox NJ, Ratain MJ, Huang RS. Genome-wide interrogation of longitudinal FEV1 in children with asthma. *Am J Respir Crit Care Med* 190, 619-627 (2014).
269. Beumer JH, Owzar K, Lewis LD, Jiang C, Holleran JL, Christner SM, Blum W, Devine S, Kolitz JE, Linker C, Vij R, Alyea EP, Larson RA, Ratain MJ, Egorin MJ. Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). *Cancer Chemother Pharmacol* 74, 927-938 (2014).
270. Wassenaar CA, Conti DV, Das S, Chen P, Cook EH, Ratain MJ, Benowitz NL, Tyndale RF. UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in European and African American smokers. *Cancer Epidemiol Biomarkers Prev* 24, 94-104 (2015).

Ratain Curriculum Vitae – Revised 7/8/2016

271. Patel JN, Jiang C, Hertz DL, Mulkey FA, Owzar K, Halabi S, Friedman PN, Ratain MJ, Morris MJ, Small EJ, Kelly WK, McLeod HL. Bevacizumab and the risk of arterial and venous thromboembolism in metastatic castration-resistant prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). *Cancer* 121, 1025-1031 (2015).
272. Maitland ML, Xu CF, Cheng YC, Kistner-Griffin E, Ryan KA, Karrison TG, Das S, Torgerson D, Gamazon E, Thomeas V, Levine MR, Wilson PA, Bing N, Liu Y, Cardon LR, Pandite LN, O'Connell JR, Cox NJ, Mitchell BD, Ratain MJ, Shuldiner AR. Identification of a variant in *KDR* associated with serum VEGFR2 and pharmacodynamics of pazopanib. *Clin Cancer Res* 15, 365-372 (2015).
273. Odenike O, Halpern A, Godley LA, Madzo J, Karrison T, Green M, Fulton N, Mattison RJ, Yee KW, Bennett M, Koval G, Malnassy G, Larson RA, Ratain MJ, Stock W. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. *Invest New Drugs* 33, 371-379 (2015).
274. Goetz MP, Sun JX, Suman VJ, Silva GO, Perou CM, Nakamura Y, Cox NJ, Stephens PJ, Miller VA, Ross JS, Chen D, Safgren SL, Kuffel MJ, Ames MM, Kalari KR, Gomez HL, Gonzalez-Angulo AM, Burgues O, Brauch HB, Ingle JN, Ratain MJ, Yelensky R. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. *J Natl Cancer Inst* 107 (2): dju401 doi:10.1093/jnci/dju401 (2015).
275. Crona DJ, Ramirez J, Qiao W, de Graan AJ, Ratain MJ, van Schaik RH, Mathijssen RH, Rosner GL, Innocenti F. Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. *Pharmacogenomics J* 16, 54-59 (2016).
276. Fleming GF, Schumm LP, Friberg G, Ratain MJ, Njiaju UO, Schilsky RL. Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion. *BMC Cancer* 15:69. doi: 10.1186/s12885-015-1075-6 (2015).
277. Ramirez J, Mirkov S, House LK, Ratain MJ. Glucuronidation of OTS167 in humans is catalyzed by UDP-glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8 and UGT1A10. *Drug Metab Disp* 43, 928-935 (2015).
278. House LK, Ramirez J, Seminerio MJ, Mirkov S, Ratain MJ. In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7. *Xenobiotica* 45, 990-998 (2015).
279. Kaufman AL, Spitz J, Yuen S, Danahey K, Saner D, Sorrentino M, Ratain MJ, O'Donnell PH. Evidence for clinical implementation of pharmacogenomics in cardiac drugs. *Mayo Clin Proc* 90, 716-729 (2015).
280. Ratain MJ, Geary D, Undevia SD, Coronado C, Alfaro V, Iglesias JL, Schilsky RL, Miguel-Lillo B. First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. *Invest New Drugs* 33, 901-910 (2015).
281. O'Donnell PH, Karovic S, Karrison TG, Janisch LA, Levine MR, Harris PJ, Polite BN, Cohen EE, Fleming GF, Ratain MJ, Maitland ML. Serum C-telopeptide collagen crosslinks and plasma soluble VEGFR2 as pharmacodynamic biomarkers in a trial of sequentially administered sunitinib and cilengitide. *Clin Cancer Res* 21, 5092-5099 (2015).
282. Dressler LG, Deal AM, Owzar K, Watson D, Donahue K, Friedman PN, Ratain MJ, McLeod HL. Participation in cancer pharmacogenomic studies: a study of 8456 patients registered to clinical trials in the Cancer and Leukemia Group B (Alliance). *J Natl Cancer Inst* 107(10). pii: djv188. doi: 10.1093/jnci/djv188 (2015).
283. Sweis RF, Drazer MW, Ratain MJ. Analysis of impact of post-treatment biopsies in phase I clinical trials. *J Clin Oncol* 34, 369-374 (2016).

Ratain Curriculum Vitae – Revised 7/8/2016

284. Seymour L, Groshen S, Rosner GL, Sullivan DM, Spriggs DR, Reeves S, Gravell A, Ivy SP, Ratain MJ. Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. *Clin Cancer Res* 21, 5057-5063 (2015).
285. Li CH, Bies RR, Wang Y, Sharma MR, Karovic S, Werk L, Edelman MJ, Miller AA, Vokes EE, Oto A, Ratain MJ, Schwartz LH, Maitland ML. Comparative effects of CT imaging measurement on RECIST endpoints and tumor growth kinetics modeling. *Clin Transl Sci* 9, 43-50 (2016).
286. Hussain S, Kenigsberg BB, Danahey K, Lee YM, Galecki PM, Ratain MJ, O'Donnell PH. Disease-drug database for pharmacogenomic-based prescribing. *Clin Pharmacol Ther* 2016 Mar 3. doi: 10.1002/cpt.364. [Epub ahead of print].
287. Nanda R, Stringer-Reasor EM, Saha P, Kocherginsky M, Gibson J, Libao B, Hoffman PC, Obeid E, Merkel DE, Khramtsova G, Skor M, Cohen RN, Ratain MJ, Fleming GF, Conzen SD. A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer. *Springerplus* 5, 947 (2016).
288. Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel JN, Halabi S, Furukawa Y, Wheeler HE, Sibley A, Lassiter C, Weisman LS, Watson D, Krens SD, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz D, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL. Pharmacogenetic discovery in CALGB (Alliance) 90401 and mechanistic validation of a VAC14 polymorphism that increases risk of docetaxel-induced neuropathy. *Clin Cancer Res*, in press (2016).
289. Hussain S, Kenigsberg BB, Danahey K, Lee YM, Galecki PM, Ratain MJ, O'Donnell PH. Disease-drug database for pharmacogenomic-based prescribing. *Clin Pharmacol Ther*, in press (2016).

Ratain Curriculum Vitae – Revised 7/8/2016

290. Other Articles, Reviews and Book Chapters

1. Golomb HM, Ratain MJ. Use in hairy cell leukemia. An update. In: Interferon Alpha-2: Pre-Clinical and Clinical Evaluation (eds. D.L. Kisner and J.F. Smyth), Martinus Nijhoff, Boston, pp. 87-92 (1985).
2. Golomb HM, Ratain MJ, Westbrook C, Daly K. The treatment of hairy cell leukemia. In: Leukemia: Recent Advances in Biology and Treatment (eds. R.P. Gale and D.W. Golde), Alan R. Liss, New York, pp 715-724 (1985).
3. Golomb HM, Ratain MJ, Vardiman JW. Sequential treatment of hairy cell leukemia; a new role for interferon. In: Important Advances in Oncology 1986 (eds. V.T. DeVita, Jr., S. Hellman and S.A. Rosenberg), J.B. Lippincott Company, Philadelphia, pp 311-321 (1986).
4. Ratain MJ, Vardiman JW, Golomb HM. The role of interferon in the treatment of hairy cell leukemia. *Semin Oncol* 13 (Suppl 2), 21-28 (1986).
5. Ratain MJ, Vogelzang NJ. Experimental rationale for continuous infusion chemotherapy. In: Cancer Chemotherapy by Infusion (ed. J.J. Lokich), Precept Press, Chicago, pp 12-34 (1987).
6. Ratain MJ, Vogelzang NJ, Bodey GP. Periwinkle alkaloids I: Vinblastine and vindesine. In: Cancer Chemotherapy by Infusion (ed. J.J. Lokich), Precept Press, Chicago, pp 167-180 (1987).
7. Bardawil RG, Ratain MJ, Golomb HM, Bitter MA, Groves C, Vardiman JW. Changes in peripheral blood and bone marrow specimens during and after interferon alfa-2b therapy for hairy cell leukemia. *Leukemia* 1, 340-343 (1987).
8. Golomb HM, Fefer A, Golde DW, Ozer H, Portlock C, Silber R, Rapoport J, Ratain MJ, Thompson J, Bonnem EM, Spiegel RJ, Tensen L, Burke JS, Vardiman JW. Sequential evaluation of alpha-2-interferon treatment in 128 patients with hairy cell leukemia. *Semin Oncol* 14 (Suppl 2), 13-17 (1987).
9. Egorin MJ, Cohen BE, Herzig RH, Ratain MJ, Peters WP. Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites in patients receiving high-dose thiotepa therapy. In: High-Dose Thiotepa and Autologous Marrow Transplantation (ed. G.P. Herzig), John Wiley and Sons, New York, pp. 3-8 (1987).
10. Golomb HM, Ratain MJ. Recent advances in the treatment of hairy cell leukemia. *N Engl J Med* 316, 870-872 (1987).
11. Golomb HM, Fefer A, Golde DW, Ozer H, Portlock C, Silber R, Rapoport J, Ratain MJ, Thompson J, Bonnem E, Spiegel R, Tensen L, Burke JS, Vardiman JW. Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa-2b. *Semin Oncol* 15 (Suppl 5), 7-9 (1988).
12. Golomb HM, Ratain MJ, Moormeier J. What is the choice of treatment for hairy cell leukemia? *J Clin Oncol* 7, 156-158 (1989).
13. Ratain MJ, Schilsky RL, Conley BA, Egorin MJ. Pharmacodynamics in cancer therapy. *J Clin Oncol* 8, 1739-1753 (1990).
14. Doane L, Ratain MJ, Golomb HM. Hairy cell leukemia: Current management. *Hematol Oncol Clin N Amer* 4, 489-502 (1990).
15. Mitchell RB, Ratain MJ, Vogelzang NJ. Experimental rationale for continuous infusion chemotherapy. In: Cancer Chemotherapy by Infusion, Second Edition (ed. J.J. Lokich), Precept Press, Chicago, pp. 3-34 (1990).
16. Ratain MJ. Monitoring plasma concentrations of clinically useful antineoplastics during continuous infusion chemotherapy. In: Cancer Chemotherapy by Infusion, Second Edition (ed. J.J. Lokich), Precept Press, Chicago, pp. 647-652 (1990).

Ratain Curriculum Vitae – Revised 7/8/2016

17. Ratain MJ, Golomb HM. Hairy cell leukemia. In: Comprehensive Textbook of Oncology, Second Edition (eds. A.R. Moosa, S.C. Schimpff, and M.C. Robson), Williams & Wilkins, Baltimore, pp. 1225-1231 (1991).
18. Mitchell RB, Ratain MJ, Vogelzang NJ. Experimental rationale for continuous infusion chemotherapy. In: Concomitant Continuous Infusion Chemotherapy and Radiation (eds. M. Rotman and C. J. Rosenthal), Springer-Verlag, Berlin, pp. 13-27 (1991).
19. Plataniias LC, Ratain MJ. Hairy cell leukaemia: The role of alpha interferon. *Eur J Cancer* 27 (Suppl 4), S53-S57 (1991).
20. Plataniias LC, Ratain MJ. Hairy-cell leukemia. In: Current Therapy in Hematology/Oncology, Fourth Edition (eds. M.C. Brain and P.P. Carbone), B. C. Decker, Philadelphia, pp. 73-79 (1992).
21. Ratain MJ, Schilsky RL. Principles of pharmacology and pharmacokinetics. In: The Chemotherapy Source Book (ed. M.C. Perry), Williams & Wilkins, Baltimore, pp. 22-35 (1992).
22. Ratain MJ, Rowley JD. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: From the bedside to the target genes. *Ann Oncol* 3, 107-111 (1992).
23. Kobayashi K, Ratain MJ. New perspectives on the toxicity of etoposide. *Semin Oncol* 19 (6 Suppl 13), 78-83 (1992).
24. Ratain MJ. Important aspects of pharmacodynamics and pharmacogenetics: considerations for use of cytotoxics. In: American Society of Clinical Oncology Educational Book, American Society of Clinical Oncology, Chicago, pp. 92-96 (1992).
25. Golomb HM, Ratain MJ, Mick R, Daly K. The treatment of hairy cell leukemia: an update. *Leukemia* 6 (Suppl 2), 24-27 (1992).
26. Schilsky RL, Ratain MJ, Vokes EE, Vogelzang NJ, Anderson J, Peterson BA. Laboratory and clinical studies of biochemical modulation by hydroxyurea. *Semin Oncol* 19 (3 Suppl 9), 84-89 (1992).
27. Ratain MJ. Therapeutic relevance of pharmacokinetics and pharmacodynamics. *Semin Oncol* 19 (4 Suppl 11), 8-13 (1992).
28. Kobayashi K, Ratain MJ. General principles of pharmacokinetics and pharmacodynamics: infusional chemotherapy. *J Infus Chemo* 2, 158-159 (1992).
29. Ratain MJ. Guest editorial. *J Infus Chemo* 2, 157 (1992).
30. Plataniias LC, Ratain MJ. Use of r-HuEPO in the treatment of the anaemia of cancer. *Erythropoiesis* 3, 107-110 (1992).
31. Mick R, Ratain MJ. Statistical approaches to pharmacodynamic modeling: motivations, methods and misperceptions. *Cancer Chemother Pharmacol* 33, 1-9 (1993).
32. Ratain MJ, Mick R, Schilsky RL, Siegler M. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. *J Natl Cancer Inst* 85, 1637-1643 (1993).
33. Ratain MJ, Schilsky RL. Pharmacology. In: Cancer Medicine, Third Edition (eds. J.F. Holland, E. Frei, R.C. Bast, et al.), Lea & Febiger, Philadelphia, pp. 671-683 (1993).
34. Kobayashi K, Ratain MJ. Individualized dosing of cancer chemotherapy. *Semin Oncol* 20, 30-42 (1993).
35. Kobayashi K, Jodrell DI, Ratain MJ. Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring. *Cancer Surv* 17, 51-78 (1993).
36. Rosner GL, Ratain MJ. Pharmacodynamics of antineoplastic agents. In: Pharmacodynamics and Drug Development: Perspectives in Clinical Pharmacology (eds. N.R. Cutler, J.J. Sramek, P.K. Narang), Wiley, Chichester, pp. 345-362 (1994).

Ratain Curriculum Vitae – Revised 7/8/2016

37. Kobayashi K, Ratain MJ. Pharmacodynamics and long-term toxicity of etoposide. *Cancer Chemother Pharmacol* 34 (Suppl), S64-S68 (1994).
38. Spielberger RT, Mick R, Ratain MJ, Golomb HM. Interferon treatment for hairy cell leukemia: an update on a cohort of 69 patients treated from 1983-86. *Leukemia Lymphoma* 14 (Suppl 1), 89-94 (1994).
39. Daugherty CK, Ratain MJ, Siegler M. Pushing the envelope: informed consent in phase I trials. *Ann Oncol* 6, 321-323 (1995).
40. Miller AA, Ratain MJ, Schilsky RL. Principles of pharmacology. In: The Chemotherapy Source Book, Second Edition (ed. M.C. Perry), Williams & Wilkins, Baltimore, pp. 27-41 (1996).
41. Ratain MJ, Mick R. Principles of pharmacokinetics and pharmacodynamics. In: Principles of Antineoplastic Drug Development and Pharmacology (eds. R.L. Schilsky, G.A. Milano, M.J. Ratain), Marcel Dekker, Inc., New York, pp. 123-141 (1996).
42. Mani S, Ratain MJ. Promising new agents in oncologic treatment. *Curr Opin Oncol* 8, 525-534 (1996).
43. Daugherty CK, Siegler M, Ratain MJ, Zimmer GD. Learning from our patients: one subject's impact on clinical research. *Ann Intern Med* 125, 892-897 (1997).
44. Boddy AV, Ratain MJ. Pharmacogenetics in cancer etiology and chemotherapy. *Clin Cancer Res* 3, 1025-1030 (1997).
45. Mani S, Ratain MJ. New phase I trial methodology. *Semin Oncol* 24, 253-261 (1997).
46. Ratain MJ, Plunkett W. Pharmacology. In: Cancer Medicine, Fourth Edition (eds. J.F. Holland, E. Frei, R.C. Bast, et al), Williams & Wilkins, Baltimore, pp. 875-889, (1997).
47. Ratain MJ. Pharmacokinetics and pharmacodynamics. In: Principles and Practice of Oncology, Fifth Edition (eds. V.T. DeVita, S. Hellman, S.A. Rosenberg), Lippincott-Raven Publishers, Philadelphia, pp. 375-385 (1997).
48. Stewart CF, Ratain MJ. Topoisomerase inhibitors. In: Principles and Practice of Oncology, Fifth Edition (eds. V.T. DeVita, S. Hellman, S.A. Rosenberg), Lippincott-Raven Publishers, Philadelphia, pp. 452-467 (1997).
49. Daugherty CK, Ratain MJ, Siegler M. Ethical issues in clinical research of cancer. In: Principles and Practice of Oncology, Fifth Edition (eds. V.T. DeVita, S. Hellman, S.A. Rosenberg), Lippincott-Raven Publishers, Philadelphia, pp. 534-542 (1997).
50. Nichols J, Foss F, Kuzel TM, LeMaistre CF, Platanius L, Ratain MJ, Rook A, Saleh M, Schwartz G. Interleukin-2 fusion protein: a novel therapy for interleukin-2 receptor expressing malignancies. *Eur J Cancer* 33 (Suppl 1), S34 – S36 (1997)
51. American Society of Clinical Oncology. Critical role of phase I clinical trials in cancer treatment. *J Clin Oncol* 15, 853-859 (1997).
52. DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. *J Clin Oncol* 16, 2557-2567 (1998).
53. Gupta E, Ratain MJ. Camptothecin analogues: topotecan and irinotecan. In: A Clinician's Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics (eds. L.B. Grochow, M. Ames), Williams & Wilkins, Baltimore, pp. 435-457 (1998).
54. DeMario MD, Ratain MJ. Rationale for phase I study of UFT plus leucovorin and oral JM-216. *Oncology* 11 (Suppl 10), 26-29 (1997).
55. Ewesuedo RB, Ratain MJ. Topoisomerase I inhibitors. *Oncologist* 2, 359-364 (1997).
56. Iyer L, Ratain MJ. Clinical pharmacology of camptothecins. *Cancer Chemother Pharmacol* 42 (Suppl), S31-S43 (1998).

Ratain Curriculum Vitae – Revised 7/8/2016

57. Iyer L, Ratain MJ. Pharmacogenetics and cancer chemotherapy. *Eur J Cancer* 34, 1493-1499 (1998).
58. Ratain MJ. New agents for colon cancer: topoisomerase I inhibitors. In: American Society of Clinical Oncology Educational Book (ed. M.C. Perry), American Society of Clinical Oncology, Alexandria, pp. 311-315 (1998).
59. Ratain MJ. Body surface area as a basis for dosing of anticancer agents: science, myth or habit? *J Clin Oncol* 16, 2297-2298 (1998).
60. Iyer L, Ratain MJ. 5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. *Cancer Invest* 17, 494-506 (1999).
61. Ratain MJ. Development of target-based antineoplastic agents. In: American Society of Clinical Oncology Educational Book (ed. M.C. Perry), American Society of Clinical Oncology, Alexandria, 71-75 (1999).
62. Ratain MJ, Ewesuedo RB. Cancer chemotherapy. In: Oncologic Therapies (eds. E.E. Vokes, H.M. Golomb), Springer, Berlin, pp. 36-118 (1999).
63. Ratain MJ. Drug combinations: dangerous liaisons or great expectations? *Ann Oncol* 10, 375-376 (1999).
64. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? *J Natl Cancer Inst* 91, 1281-1287 (1999).
65. Ratain MJ. Introduction. *Classic Papers Current Comments* 4, 1 (1999).
66. Ratain MJ. Author update: Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. *Classic Papers Current Comments* 4, 236-237 (1999).
67. Ratain MJ. Editor update: Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. *Classic Papers Current Comments* 4, 254 (1999).
68. Ratain MJ. Author update: Population pharmacodynamic study of amonafide: A Cancer and Leukemia Group B Study. *Classic Papers Current Comments* 4, 280 (1999).
69. Ratain MJ, Plunkett W. Pharmacology. In: Holland-Frei Cancer Medicine e.5 (eds. R.C. Bast Jr., D.W. Kufe, R.E. Pollock, et al.), B.C. Decker, Hamilton, pp. 589-611 (2000).
70. Stadler WM, Ratain MJ. Development of target-based antineoplastic agents. *Invest New Drug* 18, 7-16 (2000).
71. Ratain MJ. Pharmacokinetics and pharmacodynamics. In: Principles and Practice of Oncology, Sixth Edition (eds. V.T. DeVita, S. Hellman, S.A. Rosenberg), Lippincott-Williams & Wilkins, Philadelphia, pp. 335-344 (2000).
72. Ratain MJ. Insights into the pharmacokinetics and pharmacodynamics of irinotecan. *Clin Cancer Res* 6, 3393-3394 (2000).
73. Stewart CF, Ratain MJ. Topoisomerase interactive agents. In: Principles and Practice of Oncology, Sixth Edition (eds. V.T. DeVita, S. Hellman, S.A. Rosenberg), Lippincott-Williams & Wilkins, Philadelphia, pp. 415-431 (2000).
74. Innocenti F, Iyer L, Ratain MJ. Pharmacogenetics: A tool for individualizing antineoplastic therapy. *Clin Pharmacokin* 39, 315-325 (2000)
75. Kastrissios H, Ratain MJ. Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis. *Cancer Invest* 19, 57-64 (2001).
76. Ratain MJ, Relling MV. Gazing into a crystal ball - cancer therapy in the post-genomic era. *Nat Med* 7, 283-285 (2001).

Ratain Curriculum Vitae – Revised 7/8/2016

77. Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. *Invest New Drug* 19, 171-177 (2001).
78. Innocenti F, Iyer L, Ratain MJ. Pharmacogenetics of anti-cancer agents: lessons from amonafide and irinotecan. *Drug Metab Disp* 29, 596-600 (2001).
79. Miller AA, Ratain MJ, Schilsky RL. Principles of pharmacology. In: The Chemotherapy Source Book, Third Edition (ed. M.C. Perry), Lippincott Williams & Wilkins, Philadelphia, pp. 14-23 (2001).
80. Ratain MJ. Irinotecan dosing: does the CPT in CPT-11 stand for “Can’t Predict Toxicity?” *J Clin Oncol* 20, 7-8 (2002).
81. Ratain MJ. Dear Doctor: We are really not sure what dose of capecitabine you should prescribe for your patient. *J Clin Oncol* 20, 1434-1435 (2002).
82. Innocenti F, Ratain MJ. Update on pharmacogenetics in cancer chemotherapy. *Eur J Cancer* 38, 639-644 (2002).
83. Ratain MJ. PK/PD as the basis for decision making in clinical practice. In: Summary of 4th International Symposium on Measurement and Kinetics of *In Vivo* Drug Effects. (eds. M. Danhof, M. Karlsson, R.J. Powell), Leiden/Amsterdam Center for Drug Research, Leiden, pp. 182-185 (2002).
84. Ratain MJ. Pharmacogenetics and pharmacogenomics: a general overview. In: American Society of Clinical Oncology Educational Book (ed. M.C. Perry), American Society of Clinical Oncology, Alexandria, pp. 25-26 (2002).
85. Schellens JHM, Ratain MJ. Endostatin: are the 2 years up yet? *J Clin Oncol* 20, 3758-3760 (2002).
86. Schwartzmann G, Ratain MJ, Cragg GM, Wong JE, Saijo N, Parkinson DR, Fujiwara Y, Pazdur R, Newman DJ, Dagher R, Di Leone L. Anticancer drug discovery and development throughout the world. *J Clin Oncol* 20 (Suppl 1), 47S-59S (2002).
87. Nagasubramanian R, Innocenti F, Ratain MJ. Pharmacogenetics in cancer treatment. *Annu Rev Med* 54, 437-452 (2003).
88. Desai AA, Innocenti F, Ratain MJ. UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. *Pharmacogenetics* 13, 517-523 (2003).
89. Desai AA, Innocenti F, Ratain MJ. Pharmacogenomics: road to anticancer therapeutics nirvana? *Oncogene* 22, 6621-6628 (2003).
90. Innocenti F, Ratain MJ. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. *Oncology* 17 (Suppl), 52-55 (2003).
91. Ratain MJ, Plunkett WK. Pharmacology. In: Holland-Frei Cancer Medicine 6. (eds. D.W. Kufe, R.E. Pollock, R.R. Weichselbaum, et al.), B.C. Decker, Hamilton, pp. 695-710 (2003).
92. Murray PT, Ratain MJ. Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs. *J Clin Oncol* 21, 2633-2635 (2003).
93. Ratain MJ. Finding the right dose. *Clin Adv Hematol Oncol* 1, 517-518 (2003).
94. Innocenti F, Ratain MJ. “Irinogenetics” and UGT1A: from genotypes to haplotypes. *Clin Pharmacol Ther* 75, 495-500 (2004).
95. Helft PR, Ratain MJ, Epstein RA, Siegler M. Inside information: financial conflicts of interest for subjects and other non-investigator insiders in early clinical trials. *J Natl Cancer Inst* 96, 656-661 (2004).
96. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. *J Clin Oncol* 22, 4442-4445 (2004).
97. Desai AA, Ratain MJ. EGFR pharmacogenomics: the story continues to mutate and evolve. *Am J Pharmacogenomics* 5, 137-139 (2005).

Ratain Curriculum Vitae – Revised 7/8/2016

98. Ratain MJ. Phase II oncology trials: let's be positive. *Clin Cancer Res* 11, 5661-5662 (2005).
99. Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. *Nat Rev Cancer* 5, 447-458 (2005).
100. Andersson T, Flockhart DA, Goldstein DB, Huang SM, Kroetz DL, Milos PM, Ratain MJ, Thummel K. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. *Clin Pharmacol Ther* 78, 559-581(2005).
101. Ettinger DS, Ratain MJ, Cheson BD, Goldberg RM, Agus DB. Impressions from ASCO. *Clin Adv Hematol Oncol* 3, 479-483 (2005).
102. Ratain MJ, Miller AA, McLeod HL, Venook AP, Egorin MJ, Schilsky RL. The Cancer and Leukemia Group B Pharmacology and Experimental Therapeutics Committee: a historical perspective. *Clin Cancer Res* 12:3612s-3616s (2006).
103. Innocenti F, Vokes EE, Ratain MJ. Irinogenetics: what is the right star? *J Clin Oncol* 24, 2221-2224 (2006).
104. Yong WP, Innocenti F, Ratain MJ. The role of pharmacogenetics in cancer therapeutics. *Br J Clin Pharmacol* 62, 35-46 (2006).
105. Maitland ML, DiRienzo A, Ratain MJ. Interpreting disparate responses to cancer therapy: the role of human population genetics. *J Clin Oncol* 24, 2151-2157 (2006).
106. Maitland ML, Vasisht K, Ratain MJ. TPMT, UGT1A1, and DPYD: genotyping to ensure safer cancer therapy? *Trends Pharmacol Sci* 27, 432-437 (2006).
107. Michaelis LC, Ratain MJ. Measuring response in a post-RECIST world: from black and white to shades of grey. *Nat Rev Cancer* 6, 409-414 (2006).
108. Ratain MJ. From bedside to bench to bedside to clinical practice: an odyssey with irinotecan. *Clin Cancer Res* 12, 1658-1660 (2006).
109. Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, Krauss RM, McLeod HL, Ratain MJ, Relling MV, Ring HZ, Shuldiner AR, Weinshilboum RM, Weiss ST. Pharmacogenomics: challenges and opportunities. *Ann Intern Med* 145, 749-757 (2006).
110. Maitland ML, Ratain MJ. Terminal ballistics of kinase inhibitors: there are no magic bullets. *Ann Intern Med* 145, 702-703 (2006).
111. Innocenti F, Ratain MJ. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. *Pharmacogenomics* 7, 1211-1221 (2006).
112. Undevia SD, Ratain MJ, Plunkett W. Pharmacology. In: Holland-Frei Cancer Medicine 7. (eds. D.W. Kufe, R.C. Bast Jr., W.N. Hait, et al.), B.C. Decker, Hamilton, pp. 617-629 (2006).
113. Ratain MJ, Karrison TG. Testing the wrong hypothesis in phase II oncology trials: there is a better alternative. *Clin Cancer Res* 13, 781-782 (2007).
114. Ratain MJ. Personalized medicine: building the GPS to take us there. *Clin Pharmacol Ther* 81, 321-322 (2007).
115. Parsad SD, Ratain MJ. Prescribing oral chemotherapy. *BMJ* 334, 376 (2007).
116. Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, Kroetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, Reus V, Roden DM, Schaefer CA, Shuldiner AR, Skaar T, Tantisira K, Tyndale RF, Wang L, Weinshilboum RM, Weiss ST, Zineh I. The pharmacogenetics research network: from SNP discovery to clinical drug response. *Clin Pharmacol Ther* 81, 328-345 (2007).
117. Ratain MJ, Cohen EE. The value meal: how to save \$1,700 per month or more on lapatinib. *J Clin Oncol* 25, 3397-3398 (2007).
118. Maitland ML, Ratain MJ, Cox NJ. Interpreting p values in pharmacogenetic studies: a call for process and perspective. *J Clin Oncol* 10, 4313-4315 (2007).

Ratain Curriculum Vitae – Revised 7/8/2016

119. Hartford CM, Ratain MJ. Rapamycin: something old, something new, something borrowed, and now renewed. *Clin Pharmacol Ther* 82, 381-388 (2007).
120. Ratain MJ, Glassman RH. Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? *Clin Cancer Res* 15, 6545-6548 (2007).
121. Ratain MJ. The investigational drug steering committee. *Clin Adv Hematol Oncol* 5, 779-780 (2007).
122. Ratain MJ, Humphrey RW, Gordon GB, Fyfe G, Adamson PC, Fleming TR, Stadler WM, Berry DA, Peck CC. Recommended changes to oncology clinical trial design: revolution or evolution? *Eur J Cancer* 44, 8-11 (2008).
123. Daugherty CK, Ratain MJ, Emanuel EJ, Farrell AT, Schilsky RL. Ethical, scientific and regulatory perspectives regarding the use of placebos in cancer clinical trials. *J Clin Oncol* 26, 1371-1378 (2008).
124. Perera MA, Innocenti F, Ratain MJ. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? *Pharmacotherapy* 28, 755-768 (2008).
125. Zhang W, Duan S, Dolan ME, Ratain MJ. The HapMap resource is providing new insights into ourselves and its application to pharmacogenomics. *Bioinform Biol Insights* 2, 15-23 (2008).
126. Conti RM, Meltzer DO, Ratain MJ. Nonprofit biomedical companies. *Clin Pharmacol Ther* 84, 194-197 (2008).
127. Weiss ST, McLeod HL, Flockhart DA, Dolan ME, Benowitz NL, Johnson JA, Ratain MJ, Giacomini KM. Creating and evaluating genetic tests predictive of drug response. *Nat Rev Drug Discov* 7, 568-574 (2008).
128. Glassman RH, Ratain MJ. Biomarkers in early cancer drug development: limited utility. *Clin Pharmacol Ther* 85, 134-135 (2009).
129. Ratain MJ, Sargent DJ. Optimising the design of phase II oncology trials: The importance of randomization. *Eur J Cancer* 45, 275-280 (2009).
130. Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. *CA Cancer J Clin* 59, 42-55 (2009).
131. Eichelbaum M, Altman RB, Ratain M, Klein TE. New feature: pathways and important genes from PharmGKB. *Pharmacogenet Genomics* 19, 403 (2009).
132. Yang J, Bogni A, Schuetz EG, Ratain M, Dolan ME, McLeod H, Gong L, Thorn C, Relling MV, Klein TE, Altman RB. Etoposide pathway. *Pharmacogenet Genomics* 19, 552-553 (2009).
133. Sharma MR, Maitland ML, Ratain MJ. Other paradigms: Better treatments are identified by better trials: the value of randomized phase II studies. *Cancer J* 15, 426-430 (2009).
134. Plunkett WK, Ratain MJ. Pharmacology. In: Holland-Frei Cancer Medicine 8. (eds. W.K. Hong, R.C. Bast Jr., W.N. Hait, et al.), People's Medical Publishing House-USA, Shelton, CT, pp. 587-596 (2010).
135. Ramirez J, Ratain MJ, Innocenti F. Uridine 5'-diphospho-glucuronosyltransferase (UGT) genetic polymorphisms and response to cancer chemotherapy. *Future Oncol* 6, 563-585 (2010).
136. Ratain MJ, Innocenti F. Individualizing dosing of irinotecan. *Clin Cancer Res* 16, 371-372 (2010).
137. Seymour L, Ivy SP, Sargent, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. *Clin Cancer Res* 15, 1764-1769 (2010).

Ratain Curriculum Vitae – Revised 7/8/2016

138. Dancey JE, Dobbin KK, Groshwn S, Jessup JM, Hruszkewycz A, Koehler M, Ratain MJ, Shankar LK, Stadler WM, True LD, Gravell A, Grever MR. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. *Clin Cancer Res* 15, 1745-1755 (2010).
139. Maitland ML, Lou XJ, Ramirez J, Desai AA, Berlin DS, McLeod HL, Weichselbaum RR, Ratain MJ, Altman RB, Klein TE. Vascular endothelial growth factor pathway. *Pharmacogenet Genomics* 20, 346-349 (2010).
140. Ratain MJ. Bar the windows but open the door to randomization. *J Clin Oncol* 28, 3104-3106 (2010).
141. Freedman AN, Sansbury LB, Figg WD, Potosky AL, Weiss Smith SR, Khoury MJ, Nelson SA, Weinshilboum RM, Ratain MJ, McLeod HL, Epstein RS, Ginsburg GS, Schilsky RL, Liu G, Flockhart DA, Ulrich CM, Davis RL, Lesko LJ, Zineh I, Randhawa G, Ambrosone CB, Relling MV, Rothman N, Xie H, Spitz MR, Ballard-Barbash R, Doroshow JH, Minasian LM. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. *J Natl Cancer Inst* 102, 1698-1705 (2010).
142. Altman RB, Kroemer HK, McCarty CA, Ratain MJ, Roden D. Pharmacogenomics: will the promise be fulfilled? *Nat Rev Genet* 12, 69-73 (2010).
143. Ratain MJ, Collins JM, Doroshow JH. Merrill Jon Egorin, MD, 1948-2010. *Clin Pharmacol Ther* 89, 163-165 (2011).
144. de Souza JA, Polite BN, Manning WG, Fendrick AM, Ratain MJ. Value-based insurance design in oncology: bridging value, evidence, and rational drug development. *Lancet Oncol* 12, 321-323 (2011).
145. Ratain MJ. Current dilemmas in carboplatin dosing. *Clin Adv Hematol Oncol* 9, 237-238 (2011).
146. Huang RS, Innocenti F, Ratain MJ. Irinotecan. In: Pharmacogenomic Testing in Current Clinical Practice (eds. A.H.B. Wu and K.J. Yeo), Humana Press, New York, pp. 59-75 (2011).
147. Sharma MR, Stadler WM, Ratain MJ. Randomized phase II trials: a long-term investment with promising returns. *J Natl Cancer Inst* 103, 1093-1100 (2011).
148. Humphrey RW, Brockway-Lunardi LM, Dohoney KM, Doroshow JH, Meech SJ, Ratain MJ, Topalian SL, Pardoll DM. Opportunities and challenges in the design of experimental drug combinations for cancer. *J Natl Cancer Inst* 103, 1222-1226 (2011).
149. Ratain MJ. Flushing oral oncology drugs down the toilet. *J Clin Oncol* 29, 3958-3959 (2011).
150. Feuerstein, Ratain MJ. Oncology micro-cap stocks: caveat emptor! *J Natl Cancer Inst* 103, 1488-1489 (2011).
151. de Souza JA, Ratain MJ, Fendrick AM. Value-based insurance design: aligning incentives, benefits, and evidence in oncology. *J Natl Compr Canc Netw* 10, 18-23 (2012).
152. O'Donnell PH, Ratain MJ. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy. *Mol Oncol* 6, 251-259 (2012).
153. Ratain MJ. Importance of food effects for oral oncology drugs. *Clin Adv Hematol Oncol* 10, 397-398 (2012).
154. O'Donnell PH, Bush A, Spitz J, Danahey K, Saner D, Das S, Cox NJ, Ratain MJ. The 1200 Patients Project: creating a new medical model system for clinical implementation of pharmacogenomics. *Clin Pharmacol Ther* 92, 446-449 (2012).
155. Lewis LD, Ratain MJ. Might cigarettes be a “smoking gun” to reduce taxane myelotoxicity? *Clin Cancer Res* 18, 4219-4221 (2012).
156. Giacomini KM, Yee SW, Ratain MJ, Weinshilboum RM, Kamatani N, Nakamura Y. Pharmacogenomics and patient care: one size does not fit all. *Sci Transl Med* 4, 153ps18 (2012).

Ratain Curriculum Vitae – Revised 7/8/2016

157. Sharma MR, Maitland ML, Ratain MJ. RECIST: no longer the sharpest tool in the oncology clinical trials toolbox – point. *Cancer Res* 72, 5145-5149 (2012).
158. Sharma MR, Maitland ML, Ratain MJ. Why RECIST works and why it should stay – reply to counterpoint. *Cancer Res* 72, 5158 (2012).
159. Sharma MR, Maitland ML, Ratain MJ. Models of excellence: improving oncology drug development. *Clin Pharmacol Ther* 92, 548-550 (2012).
160. Pinto N, Ratain MJ. Pharmacogenomics in cancer care: adding some science to the art of medicine. *Personal Med Oncology* 1, 56-62 (2012).
161. Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ. Cancer pharmacogenomics: strategies and challenges. *Nat Rev Genet* 14, 23-34 (2012).
162. Szmulewitz RZ, Ratain MJ. Playing Russian roulette with tyrosine kinase inhibitors. *Clin Pharmacol Ther* 93, 242-244 (2013).
163. Seminerio MJ, Ratain MJ. Preventing adverse drug-drug interactions: a need for improved data and logistics. *Mayo Clin Proc* 88, 126-128 (2013).
164. Maitland ML, Schwartz LH, Ratain MJ. Time to tumor growth: a model endpoint and new metric system for oncology clinical trials. *J Clin Oncol* 31, 2070-2072 (2013).
165. Ratain MJ, Nakamura Y, Cox NJ. *CYP2D6* genotype and tamoxifen activity: understanding interstudy variability in methodological quality. *Clin Pharmacol Ther* 94, 185-187 (2013).
166. Seminerio MJ, Ratain MJ. Are drug labels static or dynamic? *Clin Pharmacol Ther* 94, 302-304 (2013).
167. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. *Nature* 501, 355-364 (2013).
168. Dolan ME, Maitland ML, O'Donnell PH, Nakamura Y, Cox NJ, Ratain MJ. University of Chicago Center for Personalized Therapeutics: research, education and implementation science. *Pharmacogenomics* 14, 1383-1387 (2013).
169. Ratain MJ, Cox NJ, Henderson TO. Challenges in interpreting the evidence for genetic predictors of ototoxicity. *Clin Pharmacol Ther* 94, 631-635 (2013).
170. Ratain MJ, Seminerio MJ. Unmet needs in preventing adverse drug-drug interactions. *Clin Adv Hematol Oncol* 11, 520-521 (2013).
171. Bins S, Ratain MJ, Mathijssen RH. Conventional dosing of anticancer agents: precisely wrong or just inaccurate? *Clin Pharmacol Ther* 95, 361-364 (2014).
172. Szmulewitz RZ, Ratain MJ. Vemurafenib bioavailability: an insoluble problem. *J Clin Pharmacol* 4, 375-377 (2014).
173. O'Donnell PH, Ratain MJ. Pharmacogenomics. In: The Molecular Basis of Cancer, Edition 4 (eds. J. Mendelsohn, J.W. Gray, P.M. Howley, et al.), Elsevier Saunders, Philadelphia, pp. 677-682 (2014).
174. Ratain MJ. Forecasting unanticipated consequences of “The Sunshine Act”: mostly cloudy. *J Clin Oncol* 32, 2293-2295 (2014).
175. Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubenstein L, Huang E, Collyar D, Groshen S, Reeves S, Ellis LM, Sargent DJ, Rosner GL, LeBlanc ML, Ratain MJ. Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. *Clin Cancer Res* 20, 4210-4217 (2014).
176. Ratain MJ. Targeted therapies: Redefining the primary objective of phase I oncology trials. *Nat Rev Clin Oncol* 11, 503-504 (2014).

Ratain Curriculum Vitae – Revised 7/8/2016

177. Ratain MJ. Incorporating biomarkers into drug labeling. Clin Adv Hematol Oncol 12, 525-528 (2014).
178. Ratain MJ, Johnson JA. Meaningful use of pharmacogenetics. Clin Pharmacol Ther 96, 650-652 (2014).
179. Conti R, Glassman R, Ratain M. New cures require new pricing policies. Health Affairs Blog (2015) (<http://healthaffairs.org/blog/2015/04/16/new-cures-require-new-pricing-policies/#comment-1315110>).
180. Moy B, Jagsi R, Gaynor RB, Ratain MJ. The impact of industry on oncology research and practice. Am Soc Clin Oncol Educ Book 35, 130-137 (2015).
181. Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, Guillemette C, Lennox JL, Whirl-Carrillo M, Brummel S, Ratain MJ, Klein TE, Schackman BR, Caudle KE, Haas DW. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing. Clin Pharmacol Ther 99, 363-369 (2016).
182. Sharma MR, Ratain MJ. Taking a measured approach to toxicity data in phase I oncology clinical trials. Clin Cancer Res 22, 527-529 (2016).
183. Rudek MA, Graham RA, Ratain MJ. Harmonization on renal function assessment is needed during early clinical development of oncology drugs. J Clin Oncol 34, 103-104 (2016).
184. Sharma MR, Ratain MJ. Pharmacology. In: Holland-Frei Cancer Medicine, Ninth Edition (eds. R.C. Bast Jr., C.M. Croce, W.N. Hait, et al.) John Wiley & Sons, Inc., Hoboken, in press (2016)
185. O'Donnell PH, Danahey K, Ratain MJ. The outlier in all of us: why implementing pharmacogenomics could matter for everyone. Clin Pharmacol Ther 99, 401-404 (2016).
186. Ratain MJ. Casting doubt on the scientific utility of post-treatment biopsies in phase 1 trials. Clin Adv Hematol Oncol 14, 78-79 (2016).
187. Yee SW, Momozawa Y, Kamatani Y, Tyndale RF, Weishilboum RM, Ratain MJ, Giacomini KM, Kubo M. Genomewide association studies in pharmacogenomics: meeting report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration. Clin Pharmacol Ther, in press (2016).

Ratain Curriculum Vitae – Revised 7/8/2016

Books

1. Schilsky RL, Milano GA, Ratain MJ. Principles of Antineoplastic Drug Development and Pharmacology, Marcel Dekker, Inc., New York (1996).
2. Ratain MJ, Tempero M, Skosey C. Outline of Oncology Therapeutics, W.B. Saunders, Philadelphia (2001).

Ratain Curriculum Vitae – Revised 7/8/2016

Letters, and Book Reviews

1. Vogelzang NJ, Ratain MJ. Cancer chemotherapy and skin changes (Letter). Ann Intern Med 103, 303-304 (1985).
2. Ratain MJ, Schilsky RL. Correspondence re: M.J. Egorin et al. Human pharmacokinetics, excretion and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities (Letter). Cancer Res 46, 4874 (1986).
3. Ratain MJ, Golomb HM. Hairy cell leukemia (Letter). N Engl J Med 317, 902 (1987).
4. Ratain MJ, Schilsky RL, Staubus AE, Malspeis L. Reply (Letter). Cancer Res 49, 3139-3140 (1989).
5. Ratain MJ, Schilsky RL. Response (Letter). J Natl Cancer Inst 81, 1510 (1989).
6. Mick R, Ratain MJ, Golomb HM. Duration of response after interferon treatment of hairy cell leukemia (Letter). Blood 75, 2465-2466 (1990).
7. Ratain MJ. Book review: Cancer Chemotherapy: Principles and Practice. J Natl Cancer Inst 82, 1644-1645 (1990).
8. Ratain MJ. Dose reduction of etoposide in jaundiced patients (Letter). J Clin Oncol 8, 2088 (1990).
9. Richards JM, Mick R, Latta JM, Daly K, Ratain MJ, Vardiman JW, Golomb HM. Response (Letter). Blood 77, 2541-2542 (1991).
10. Stock W, Lichtman S, Ratain MJ, O'Brien S, Vogelzang NJ, Van Echo DA. Response to high dose cyclophosphamide with GM-CSF in Merkel cell tumor (Letter). Ann Oncol 2, 522-523 (1991).
11. Larson RA, Le Beau MM, Ratain MJ, Rowley JD. Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia (Letter). Blood 79, 1892-1893 (1992).
12. Barton K, Larson RA, O'Brien S, Ratain MJ. Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine (Letter). J Clin Oncol 10, 1821 (1992).
13. Kobayashi K, Vokes EE, Stefansson K, Janisch L, Vogelzang NJ, Berezin F, Ratain MJ. Suramin: Is adaptive control necessary? (Letter). J Clin Oncol 10, 1984-1985 (1992).
14. Mick R, Ratain MJ. Phase I study of escalating doses of carboplatin (Letter). Cancer Chemother Pharmacol 34, 535-536 (1994).
15. Miller AA, Lilenbaum RC, Lynch TJ, Rosner GL, Ratain MJ, Green MR, Schilsky RL. Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel (Letter). J Clin Oncol 14, 1964-1965 (1996).
16. Kobayashi K, Vokes EE, Vogelzang NJ, Janisch L, Soliven B, Ratain MJ. Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose (Letter). J Clin Oncol 14, 2622-2623 (1996).
17. Kobayashi K, Vokes EE, Vogelzang NJ, Ratain MJ. Data modifications to phase I study of suramin (Letter). J Clin Oncol 14, 2623-2624 (1996).

Ratain Curriculum Vitae – Revised 7/8/2016

18. Ratain MJ, Sheridan ME. Conflict-of-interest policies (Letter). N Engl J Med 344, 1018 (2001).
19. Innocenti F, Ratain MJ. Correspondence re: Raida, M. et al., Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU) related toxicity compared with controls. (Letter). Clin Cancer Res 8, 1314-1316 (2002).
20. Karrison T, Ratain MJ. Troxacitabine in patients with refractory leukemia (Letter). J Clin Oncol 20, 3356-3357 (2002).
21. Liu W, Innocenti F, Ratain MJ. Linkage disequilibrium across the UGT1A locus should not be ignored in association studies of cancer susceptibility (Letter). Clin Cancer Res 11, 1348-1349 (2005).
22. Stadler WM, Michaelis LC, Ratain MJ. Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing? (Letter). J Clin Oncol 23, 8124-8125 (2005).
23. Ratain MJ. In reply (Letter). J Clin Oncol 24, 4670-4671 (2006).
24. O'Donnell PH, Ratain MJ. Evaluating the activity of temsirolimus in neuroendocrine cancer (Letter). Br J Cancer 96, 177 (2007).
25. Altman RB, Benowitz N, Gurwitz D, Lunshof J, Relling M, Lamba J, Wieben E, Mooney S, Giacomini K, Weiss S, Johnson JA, McLeod H, Flockhart D, Weinshilboum R, Shuldiner AR, Roden D, Krauss RM, Ratain M. Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing (Letter). Pharmacogenomics 8, 519 (2007).
26. Chabner BA, Ratain MJ. Clarification regarding "Phase II Trials Published in 2002: A Cross-Specialty Comparison Showing Significant Design Differences between Oncology Trials and Other Medical Specialties" and the accompanying commentary, "Phase II Cancer Trials: Out of Control?" (Letter). Clin Cancer Res 13, 6540 (2007).
27. Ratain MJ, Cohen EE. In reply (Letter). J Clin Oncol 25, 5334-5335 (2007).
28. Ratain MJ, Glassman RH. Reply to the letter to the editor from Banerji et al (Letter). Clin Cancer Res 14, 2514 (2008).
29. Ratain MJ. Reply to M. Todd et al (Letter). J Clin Oncol 30, 889 (2012).
30. Ratain MJ. Reply to M. N. Needle (Letter). J Clin Oncol 30, 890 (2012).
31. Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA. Re: *CYP2D6* genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 Trial (Letter). J Natl Cancer Inst 104, 1264 (2012).
32. Goetz MP, Brauch H, Ratain MJ, Cox NJ, Nakamura Y, Weinshilboum R, Ingle JN. Re: Concordance between *CYP2D6* genotypes obtained from tumor-derived and germline DNA (Letter). J Natl Cancer Inst 106, dju063 (2014).
33. de Souza J, Yap B, Ratain MJ, Daugherty C. User beware: we need more science and less art when measuring financial toxicity in oncology (Letter). J Clin Oncol 33, 1414-1415 (2015).
34. Sweis RF, Ratain MJ. Reply to T.A. Yap et al (Letter). J Clin Oncol 33, 2432-2433 (2016).

Ratain Curriculum Vitae – Revised 7/8/2016

35. Goetz MP, Ratain MJ, Ingle JN. Providing balance in ASCO Clinical Practice Guidelines: *CYP2D6* genotyping and tamoxifen efficacy. *J Clin Oncol*, in press (2016).